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Resumo 
 
A comunicação celular é fundamental para os processos biológicos no desenvolvimento e na 
vida adulta. Um dos sistemas mais utilizados por eucariotas é a via de sinalização Notch. Existem 
quatro recetores e cinco ligandos em mamíferos, cujos domínios extracelulares interagem, ativando a 
transcrição. Foi demonstrado que a expressão dos ligandos não é detetável em tecidos normais, mas 
que expressão moderada a elevada foi detetada em cancro da mama. Assim, qualquer um dos 
ligandos da via Notch pode ser estudado como possível alvo terapêutico. 
O nosso objetivo é determinar as melhores condições de expressão e purificação para os 
ligandos da via Notch para poder desenvolver anticorpos contra essas proteínas pela tecnologia de 
"Phage-Display". Queremos ainda cristalizar os ligandos do Notch e também o(s) complexo(s) com os 
anticorpos selecionados, revelando detalhes moleculares. 
Para estudar proteínas é necessário obtê-las de forma estável em solução. E. coli é o hospedeiro 
de excelência para expressar proteínas recombinantes dada a facilidade, rápido crescimento e altas 
densidades celulares. No entanto, a expressão de proteínas de mamíferos em tais sistemas pode 
sobrecarregar a maquinaria celular bacteriana, que não possui a capacidade para modificações pós-
translacionais ou compartimentos específicos para a síntese proteica. As células de mamíferos são 
portanto preferidas, embora as exigências técnicas e financeiras sejam maiores. 
As proteínas hJag2DE3 e hDll1DE6 foram purificadas a partir de corpos de inclusão e 
sobrenadante de cultura de células de mamífero, respetivamente, e a pureza confirmada por SDS-
PAGE (> 95%). A proteína produzida em células de mamífero mostrou-se mais estável e aparenta ter 
o padrão fisiológico de pontes dissulfureto, ao contrário do que foi observado na proteína "refolded". 
Diversas cristalizações em nano-escala foram realizadas em placas de 96 poços, sem resultados 
positivos. 
Iremos continuar a estudar a melhor condição de expressão para os ligandos do Notch em 
ambos os sistemas de expressão. 
 
Palavras-chave: Via de sinalização Notch, Cancro da mama, Expressão de proteínas 
recombinantes, cristalização de macromoléculas. 
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Abstract 
 
Cell-to-cell communication is required for many biological processes in development and adult 
life. One of the most common systems utilized by a wide range of eukaryotes is the Notch signalling 
pathway. Four Notch receptors and five ligands have been identified in mammals that interact via their 
extracellular domains leading to transcription activation. Studies have shown that the Notch ligands 
expression is undetectable in normal breast tissues, but moderate to high expression has been 
detected in breast cancer. Thus, any of the Notch1 ligands can be studied as possible therapeutic 
targets for breast cancer. 
To study Notch pathway proteins there is the need to obtain stable protein solutions. E. coli is the 
host of excellence for recombinant proteins for the ease of use, fast growth and high cell densities. 
However, the expression of mammalian proteins in such systems may overwhelm the bacterial cellular 
machinery, which does not possess the ability for post-translational modifications, or dedicated 
compartments for protein synthesis. Mammalian cells are therefore preferred, despite their technical 
and financial increased demands. 
We aim to determine the best expression and purification conditions for the different ligand 
protein constructs, to develop specific function-blocking antibodies using the Phage Display 
technology. Moreover, we propose to crystallize the Notch1 ligands alone and in complex with the 
phage display selected antibodies, unveiling molecular details. 
hJag2DE3 and hDll1DE6 proteins were purified from refolded inclusion bodies or mammalian cell 
culture supernatants, respectively, and purity was confirmed by SDS-PAGE (>95%). Protein produced 
in mammalian cells showed to be more stable, apparently with the physiological disulfide pattern, 
contrary to what was observed in the refolded protein. Several nano-scale crystallization experiments 
were set up in 96-well plates, but no positive result was obtained. 
We will continue to pursue for the best expression for the Notch ligand constructs in both 
expression systems. 
 
Keywords: Notch signalling, Breast cancer, Recombinant protein expression, Macromolecular 
crystallisation. 
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Chapter I Introduction 
 
The Notch Signalling Pathway is a highly conserved cell signalling system present in most 
multicellular organisms. Signals exchanged between neighbouring cells through the Notch receptor 
can amplify and consolidate molecular differences, which eventually dictate cell fates. Thus, Notch 
signals control how cells respond to intrinsic or extrinsic developmental cues that are necessary to 
unfold specific developmental programs (Artavanis-Tsakonas, Rand et al. 1999). The Notch signalling 
pathway plays a crucial role in multiple cellular processes including stem cell self-renewal, cell fate 
determination, epithelial cell polarity/adhesion, cell division and apoptosis (Wu, Cain-Hom et al. 2010). 
Different Notch receptors with specific functions have been identified but, interestingly, they all trigger 
the activation of the same downstream cascade. 
I.1. Notch signalling pathway overview 
The Notch signalling pathway involves direct contact of two adjacent cells with distinct molecular 
signatures; one cell expressing the Notch receptor and the other the Notch ligand (Figure I.1). Both 
Notch receptors and ligands are type I transmembrane proteins with a series of tandem Epidermal 
Growth Factor-like Repeats (herein referred as EGFs). For signalling to be productive, the receptor 
and ligand binding through the EGF domains takes place in trans, ie. both proteins are expressed in 
different cells and the polypeptide chains are inversely oriented respective to each other. When both 
receptor and ligand proteins are expressed in the same cell, proteins are able to bind in cis, albeit 
resulting in signalling inhibition. 
At a given time, a cell can only be in a "sending" state, where predominantly the ligand is 
expressed on the cell surface, or in a "receiving" state, where the receptor is the most abundant 
(Figure I.1). A model with the two mutually exclusive states for Notch signalling was previously 
proposed (Sprinzak, Lakhanpal et al. 2010) to explain both graded trans-activation and sharp cis-
inhibition: in the "signal receiving" cell the Notch receptor binds to the ligand of the "signal sending" 
cell, and is activated in a ligand exposition dependent manner. Consequently the Notch Intracellular 
Domain (NICD) migrates to the nucleus where it participates in transcription complexes; alternatively, 
the Notch receptor in the "signal receiving" cell also binds irreversibly to the ligand expressed in the 
same cell, and the complex is internalised without NICD release. This model is in agreement with the 
previously described requirement of Notch Extracellular Domain (NECD) trans-endocytosis by the 
ligand expressing cell for Notch receptor proteolysis events (Nichols, Miyamoto et al. 2007). 
The very first proteolytic event of the Notch receptor polypeptide chain takes place in the Golgi 
apparatus by a Furin-like protease, generating a mature receptor in a heterodimeric form joined by 
non-covalent interactions (Kopan and Ilagan 2009). As depicted in Figure I.1, upon ligand binding 
Notch receptor is cleaved at two sites in a consecutive order - first by ADAM/TACE at site 2 (S2) and 
afterwards by γ-secretase at site 3 (S3). These three proteolytic events are necessary, in that order, 
for active NICD generation and in order for productive signalling to occur. When not processed by 
Furin in the Golgi, the Notch receptor exists in the immature form at the cell surface and, although 
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capable of ligand binding, it fails to generate productive signalling due to losses in receptor 
dissociation. ADAM proteolysis at S2 is required for NICD formation given that if ADAM proteolysis is 
inhibited, gamma-secretase is not able to cleave at S3, thereby releasing the active NICD to the 
cytoplasm (Nichols, Miyamoto et al. 2007). 
 
 
Figure I.1 - Overview of Notch canonical signalling pathway. Notch signalling is initiated by the 
interaction of Notch receptor with DSL ligands (Jagged and Delta in mammalian cells) via their 
extracellular domains. This interaction requires two adjacent cells, a signal sending cell (bottom 
corner) expressing a ligand and a signal receiving cell (top corner) expressing the receptor. Upon 
ligand binding, Notch receptor is proteolysed by ADAM protease, permitting a second, 
intramembrane cleavage event by gamma-secretase. Notch intracellular domain (NICD) is then 
able to translocate to the nucleus where it forms a transcription activating complex. Endocytosis of 
Notch extracellular domain (NECD) by the signal sending cell (trans-endocytosis), is thought 
generate the pulling forces needed to mediate a conformational change in the receptor’s negative 
regulatory region (NRR) (Nichols, Miyamoto et al. 2007), where the proteolysis sites are buried, 
making S2 and S3 sites accessible for proteases. Figure from Wang (2011). 
 
Notch signalling occurs through the direct interaction of one ligand protein with one receptor 
protein, releasing one NICD that will form one transcription activation complex. This specifies Notch 
signalling as a time-, space- and dose-dependent pathway (Rizzo, Osipo et al. 2008, South, Cho et al. 
2012). 
 
I.2. 100 year-lesson on Notch 
Nearly a century after the description of a notched wing phenotype in Drosophila melanogaster by 
John S. Dexter in 1914, the scientific community is now starting to understand the complex and 
intricate Notch signalling pathway. The last 20 years of research contributed to a gradual increase on 
the knowledge of the roles, molecular players and interplays of Notch signalling. 
Using D. melanogaster as a model organism, Artavanis-Tsakonas' group reported Notch 
receptor-ligand interactions via the proteins' extracellular region domains when expressed in adjacent 
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cells (in trans) and proposed that protein interactions could also occur in cis (when both receptor and 
ligand proteins are expressed in the same cell) (Fehon, Kooh et al. 1990). 
Shortly after, Notch signalling was implicated in neural development (Heitzler and Simpson 1993) 
and the signal transduction mechanism assigned to its intracellular domain, whereas signal regulation 
would occur through the Notch extracellular domain (Greenwald 1994). Some 20-year-old research 
and review articles from the era of Notch signalling ground-breaking discoveries compiled knowledge 
that is still widely accepted in the field (Heitzler and Simpson 1993, Zagouras, Stifani et al. 1995, 
Robey 1997, Fleming 1998), and these reports were the first reasoning of a great amount of data in D. 
melanogaster, C. elegans and mammalian systems. 
 
I.3. Notch receptor and ligand proteins 
In mammals, four Receptors (Notch1-4) and five Ligands (Jagged1/2 – Jag1/2, and Delta-like 
protein 1, 3 and 4 - Dll1, Dll3 and Dll4) have been identified, as depicted in Figure I.2. All family 
members are type I transmembrane proteins that contain 6-36 EGF-like repeats in the extracellular 
domain. 
 
Figure I.2 – Domain organization of the canonical regulators of Notch signalling pathway. 
Adapted from Kopan and Ilagan (2009), Wang (2011) and South, Cho et al. (2012). 
 
In addition, Notch signalling protein members have the following molecular features: 
1) The receptor proteins have a Negative Regulatory Region (NRR) in the extracellular domain 
composed by three Lin12-Notch Repeats (LNR) and an Heterodimerization Domain (HD), harbouring 
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the S2 and S3 proteolytic sites. Notch Intracellular Domain (NICD) contains Nuclear Localization 
Signals (NLS) that target it to the nucleus, a Rbp-associated Molecule (RAM), and seven Ankyrin 
Repeat domains (ANK) that are capable of protein binding and transcription activation. These 
receptors also contain a C-terminal PEST domain that targets NICD for degradation. 
2) The Notch ligands have a Module N-terminal of Notch Ligands (MNNL) followed by a 
Delta/Serrate/LAG-2 (DSL) domain. The ligands can be subdivided in DOS/DSL ligands, containing 
the Delta and OSM-Like domains (DOS) (Jag1/2 and Dll1), and DSL only ligands. Jagged1 and 2 
have an additional Cysteine-Rich (CR) domain (Schofield, Pope et al. 2007). 
 
As stated above, receptor-ligand interactions occur via the extracellular EGF-Like repeats. The 
minimal binding region has been assigned to EGF11 to 13 of Notch receptor, and to DSL to EGF3 of 
Jagged proteins (Shimizu, Chiba et al. 1999) by a series of cell-based and solid-phase binding assays, 
using combinations of mutated Jagged1 and receptor proteins, in a calcium-dependent manner. 
Previous studies in D. melanogaster had already demonstrated that Notch signalling proteins 
interacted via the extracellular domains with specificity, and that Notch EGF 11-12 are both necessary 
and sufficient for binding, constituting the receptor's minimal binding region (Fehon, Kooh et al. 1990, 
Rebay, Fleming et al. 1991). Furthermore, Notch receptor interacts with more than one Drosophila 
ligand in both cell based and in vivo assays (Rebay, Fleming et al. 1991). The importance of other 
Notch domains (such as EGFs 24-30, Abruptex region) was proposed based on in vivo observations 
in mosaic Drosophila models (Heitzler and Simpson 1993), expressing both Abruptex region mutant 
and wild-type Notch receptor. By analysing the cell fate decisions in the cell margins it was postulated 
that only the Abruptex mutant cells are influenced by the wt neighbour cells and not the other way 
around, reinforcing Notch role as a receptor. Recently, Dighe and colleagues demonstrated that Notch 
EGFs 11-15 in fact interact in vitro with EGFs 21-30 with a 10-fold higher affinity than for its ligands. 
The critical domains in Abruptex region for ligand binding and receptor activation was narrowed to 
Notch EGFs 25-26 in antibody-based experiments where a blockage of this two EGF repeats of Notch 
Receptor abolished ligand binding to Notch EGFs 11-13. Therefore, they proposed that in the basal 
state Notch receptor may be kept in an inactive form by tight interaction between these two distant 
regions of Notch (EGFs 25-26 and 11-13), which can be disrupted upon ligand binding, causing a 
conformational change permitting receptor activation (Sharma, Rangarajan et al. 2013). 
 
To better understand the role of the extracellular domains of the Notch signalling components, 
Cordle, Johnson et al, (2008) solved the first X-Ray crystal structure of Jagged1 comprising the 
minimal binding region, ie., DSL through EGF3 domains, and recently a structure comprising also the 
MNNL domain was reported (Chillakuri, Sheppard et al. 2013) (Figure I.3). The structures reveal a 
near-linear arrangement of the domains, irrespective of the MNNL domain presence. 
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Figure I.3 – Structural models of Jagged 1. A) Jagged1 DSL-EGF3 domains, residues 187 to 
335 (top, PDB: 2VJ2; (Cordle, Johnson et al. 2008)) and B) MNNL-EGF3 domains, residues 32 to 
335 (bottom, PDB: 4CC0; (Chillakuri, Sheppard et al. 2013)). Cartoon representations generated 
using PyMOL (http://www.pymol.org) coloured from blue at the N-Terminus to red in the C-
Terminus. Disulfide bonds are shown as light grey sticks. 
 
The DSL domain has an EGF-like fold, albeit its dissulfide pattern (C1-C2, C3-C4, C5-C6) is not 
conserved. This domain shows a face with highly conserved residues, crucial for Notch binding 
(Cordle, Johnson et al. 2008). EGFs 1 and 2 show a truncated structure compared with other EGFs, 
between cysteine 3 (C3) and cysteine 4 (C4), while maintaining the EGF characteristic dissulfide 
pattern of C1-C3, C2-C4, C5-C6. The MNNL domain presents a C2 fold domain with a beta-sandwich 
of 8 β-strands. Human Jagged1 C2 or MNNL domain has high structural similarity with the Munc13-1 
C2b domain with a r.m.s.d. (root-mean-square deviation) of 2.7Å despite only 10% sequence 
homology. As a C2 domain, MNNL retains the ability to bind phospholipids in a calcium-dependent 
manner, suggesting a modulation role of this domain in the signalling process (Chillakuri, Sheppard et 
al. 2013). 
 
I.4. Notch in development and disease (cancer) 
Notch signalling pathway is involved in several aspects of development, homeostasis and cell 
fate determination both in invertebrates and vertebrates (Robey 1997, Artavanis-Tsakonas, Rand et 
al. 1999, Wang 2011). Soon after the burst of knowledge on invertebrate Notch signalling, mammalian 
Notch ligands were identified in rat (Lindsell, Shawber et al. 1995) and mouse (Shimizu, Chiba et al. 
1999). In the same year, Notch signalling involvement in oncogenic processes was the first normal 
and cell-fate-determining mechanism reported to have such role (Zagouras, Stifani et al. 1995), hence 
providing new research avenues and intricacies to the already highly populated components of this 
signalling pathway.  
Mutations in the Notch receptors that may cause an exacerbated Notch signalling response, 
similar to the pathway’s normal function of the given tissue, have been involved in B cell malignancies 
and T-cell acute lymphoblastic leukemia (T-ALL). Those mutations lead to an increased NICD half-life, 
and to an elevated nuclear activity by disrupting either the C-Terminal PEST sequences (responsible 
for NICD targeting for degradation), or the Negative Regulatory Region (that allow proteolysis events 
to activate Notch in a ligand-independent manner) (Figure I.2) (South, Cho et al. 2012). Sethi, Dai et 
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al. (2011) reported that the Jagged1 ligand, and not other pathway components, contributes to the 
metastatic ability of breast cancer cells towards bone through TGF-β (a pro-metastatic cytokine). 
Moreover, the report shows that γ-secretase inhibitors (GSIs) can inhibit breast cancer bone 
metastasis by disruption of Notch signalling pathway between breast cancer cells and stromal bone 
cells. GSIs are small molecules that are being studied as candidate therapeutic agents (Rizzo, Osipo 
et al. 2008) but are not specific neither for Notch signalling pathway or cancer treatments (Purow 
2012). These small molecules already entered clinical trials but provoke mainly intestinal toxicity 
deregulating Notch signalling, important for intestinal epithelial cell differentiation, and causing goblet 
cell metaplasia (van Es, van Gijn et al. 2005). As such, tissue specific therapies, rather than systemic 
inhibition or blockage on Notch receptors, are needed that act in a target dependent manner. The 
development of therapies with a very specific and restricted expression pattern may result in the 
generation of good candidates for biological treatments, reducing mechanism based toxicities (Rizzo, 
Osipo et al. 2008). 
Notch signalling is also involved in physiological angiogenesis regulation. Sprout tip cells express 
high levels of Delta-Like Ligand4 that activate Notch1 in adjacent cells in response to Vascular 
Endothelial Growth Factor (VEGF) (Garcia and Kandel 2012). Disruption of Dll4 signalling enhances 
angiogenic sprouting in a tumour environment, and is thought that this deregulated sprouting can 
cause non-productive angiogenesis, leading to tumour regression due to poor perfusion and increases 
in hypoxia. Ridgway, Zhang et al. (2006) reported that a neutralizing Dll4 antibody that blocks Notch 
signalling, and inhibits tumour growth in a VEGF-dependent manner, has the ability to reduce tumour 
size in several solid tumour models, without intestinal toxicity, as seen with the use of GSIs. This study 
demonstrated how tumour regression was accomplished without compromising the expression of 
Notch target genes, providing the proof of concept that a targeted biological treatment can in fact be 
more promising. Nevertheless, the same group reported recently that chronic blockade of Notch/Dll4 
pathway with the neutralizing Dll4 antibody in adult mice increases the expression of several 
endothelium-specific genes, having a negative impact in liver homeostasis, and increasing the 
incidence of ulcerating subcutaneous tumours in male rats (Yan, Callahan et al. 2010), precluding the 
continuous use of this particular antibody in a treatment regimen. 
Furthermore, recent studies have implicated aberrant Notch signalling in breast cancers. High 
level expression of Notch receptors and ligands, and their increased activation in several breast 
cancers and early precursors, place Notch signalling as a key player in breast cancer pathogenesis 
(Mittal, Subramanyam et al. 2009). Notch signalling genes – Notch1 and Jagged1 – have been shown 
to be potential prognostic markers for breast cancer (Sethi, Dai et al. 2011), and the expression of 
Notch1 ligand Jagged2 has also been correlated with the overall- and metastasis-free survival of 
breast cancer patients (Xing, Okuda et al. 2011). Mittal, Subramanyam et al. (2009) have also shown 
that Delta-like-1 expression is undetectable in normal breast tissues, but moderate to high expression 
has been detected in breast cancer. Thus any of the Notch1 ligands can be studied as possible 
therapeutic targets for breast cancer. 
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Structural models are very useful to allow understanding many biological pathways. As such, 
determination of the crystal structures of Notch ligands would allow determining the molecular basis of 
antagonistic activity in the Notch1 signalling pathway. However, it is first necessary to obtain a pure 
and homogeneous protein solution prior to crystallization experiments, biophysical characterisation 
and other in vitro research strategies. To further dissect the different roles of each of the Notch ligands 
domains, there is the need to obtain truncated versions of the target proteins, engineering DNA 
constructs bearing the desired sequences and heterologously express the respective recombinant 
proteins. 
 
I.5. Recombinant Protein production strategies 
Recombinant protein production requires a host organism that may not always necessarily be the 
original organism of the protein to be expressed.  
I.5.1 Protein expression in E. coli  
The normal first approach for recombinant protein production relies in the use of bacterial cells, 
namely Escherichia coli. This allows for a fast and cost effective production of large amounts of protein 
(Jonasson, Liljeqvist et al. 2002). The majority of structural data deposited in the Protein Data Bank 
(PDB) has relied in protein produced in E. coli, summing up to 80% in 2003 (Sorensen and Mortensen 
2005). 
In spite of the advantages of using E. coli as a host for recombinant protein production, there are 
several drawbacks, especially when dealing with eukaryotic (human) proteins as the codon usage 
between the two organisms is considerably different and rare codons tend to stall translation 
(Jonasson, Liljeqvist et al. 2002, Gustafsson, Govindarajan et al. 2004). To overcome this potential 
problem, gene synthesis of codon optimized genes or the use of host strains co-expressing rare 
tRNAs are the most standard strategies. Without the usage of these strains the presence of rare 
codons can decrease target protein quantity and quality, overwhelming of the available rare tRNA 
polls, and provoking translational errors (Jonasson, Liljeqvist et al. 2002, Gustafsson, Govindarajan et 
al. 2004, Jana and Deb 2005). Codon optimization of the desired gene sequence modifies the 
problematic codons present in the native gene, but that have a low frequency of usage (mostly in the 
third ‘wobble’ position), in such a way that the protein sequence of interest is maintained. The use of 
an optimized gene sequence can increase the recombinant protein expression up to 10-20% of total 
E. coli protein when compared to the native’s gene sequence for expression (Gustafsson, 
Govindarajan et al. 2004). Whenever it is not possible, or when it is too expensive to obtain gene 
optimized sequences, non-optimized genes can be expressed using host strains that co-express rare 
tRNAs; those are commercially available with different names from a number of suppliers such as 
Stratagene’s BL21 CodonPlus or Rosetta from Novagen, an expression host strain transformed with 
the pRARE plasmid. 
Moreover, eukaryotic proteins may not fold correctly in E. coli cytoplasm due to improper redox 
conditions and be accumulated as inclusion bodies. In order to increase protein solubility there are 
various approaches to consider, either alone or in combination: 1) Reducing protein synthesis rate by: 
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using a weak or a moderately strong promoter, by partially inducing a strong promoter, or by 
decreasing the temperature; 2) Using a highly soluble fusion partner that drives the overall solubility of 
the fusion protein, such as Maltose-binding Protein (MBP), Small Ubiquitin Modifier (SUMO), 
Glutathione S-Transferase (GST) and Thioredoxin (Trx); and 3) Co-expressing molecular chaperones 
that drive partially or unfolded peptides to adopt the native conformation such as DnaK-DnaJ-GrpE, 
ClpB, GroEL-GroES, and IbpA/B (Jonasson, Liljeqvist et al. 2002, de Marco, Vigh et al. 2005, Jana 
and Deb 2005, Bell, Engleka et al. 2013). The successful application of one or a combination of the 
mentioned approaches is determined experimentally and in an empirical basis; in many cases though, 
upon over-expression, recombinant protein is stored as aggregates in Inclusion Bodies (Shimizu, 
Chiba et al. 1999). Additionally, modified strains that allow for disulfide bond formation in E. coli 
cytoplasm such as Origami and derivatives (Novagen) and SHuffle (Lobstein, Emrich et al. 2012) have 
been developed. Moreover, bacteria do not possess the cellular machineries for post-translational 
modifications (PTM) (Jana and Deb 2005) such as glycosylation and phosphorylation. This poses the 
concern when expressing mammalian/human proteins, such as the domains of Notch ligand proteins, 
as there are predicted sites for PTMs in their sequences (http://www.uniprot.org/; Accession numbers: 
hJagged1 - P78504, hJagged2 - Q9Y219, hDelta-like Ligand1 - O00548).  
I.5.2 Protein expression in Eukaryotic systems 
To overcome part of the disadvantages of bacterial expression mentioned above, mammalian 
expression systems can be utilized for the production of human proteins. Both murine and human cells 
possess all the required machinery for folding, disulfide bond formation and PTM for eukaryotic protein 
synthesis, in dedicated cellular compartments that provide the necessary and different environments, 
and the machinery for each stage of protein production. The most used cell lines for protein production 
cited in the literature are CHO cells (Chinese Hamster Ovarian cells, a murine cell line), and HEK cells 
(Human Embryonic Kidney, a human cell line). The choice of cell line lies in specific needs either for 
productivity or fidelity in terms of molecular structure and biochemical proprieties, lying the choice 
between CHO or HEK cell lines, respectively (Swiech, Picanco-Castro et al. 2012). 
Unfortunately, the use of mammalian cells as expression host poses different challenges in both 
technical and financial points of view when compared to bacterial expression systems. There are two 
strategies for protein expression using mammalian cells, Transient and Stable Gene Expression (TGE 
and SGE, respectively). The generation of stable expression clones for SGE requires the integration of 
the gene of interest, transfected as for TGE, in the cells' genome, followed by a time-consuming 
selection and characterization process of the generated clonal cells. For that reason, when multiple 
targets are to be expressed, a TGE approach is preferred (Swiech, Picanco-Castro et al. 2012, 
Diepenbruck, Klinger et al. 2013). Being technically less difficult than SGE, cell culture maintenance 
for TGE requires specialized training and a great amount of operator hours. Generally, the plasmids 
used for TGE have the gene of interest controlled by a constitutive promotor and for that reason, 
cultures must be expanded prior plasmid DNA transfection in a large scale, increasing the total 
amount of DNA and transfection reagents required. These are of course scaled accordingly to the final 
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culture volume required for each experiment. Moreover, it is imperative to use high quality DNA and 
transfection reagents (Zhao, Bishop et al. 2011), increasing the total cost per protein production.  
Regardless of the technical difficulties encountered when dealing with mammalian cells as hosts 
for protein expression, this may me a safe option to generate human proteins amenable for purification 
and subsequent studies, in case bacterial expression fails. 
 
 
I.6. Aim of this thesis 
 
The present study aims to unveil the best expression and purification conditions for truncated 
domains of the extracellular domains of canonical Notch ligands. The major goal is to express and 
purify the Notch1 ligand proteins and use them as antigens to generate specific antibodies employing 
Phage Display technology, for target specific therapeutics. Also, and since to date there are no 
complete structural models of any of the Notch1 ligands, the objective is to determine the crystal 
structures of full-length or partial Jagged1 and 2 and Delta-Like Ligand1 proteins, alone and in 
complex with the generated antibodies, by X-Ray crystallography. 
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Chapter II  Methods1 
II.1. Molecular Biology 
All primer oligonucleotides synthesis and DNA sequencing services were purchased from 
STABVida, Portugal. Human Jagged1 (Gene Bank Ref.IDnm_000214.2) and human Delta-like ligand1 
(Gene Bank Ref.IDnm_005618.3) cDNAs were purchased from SinoBiological (Cat# HG11648-M and 
HG11635-M, respectively). Human Jagged2 (Gene Bank Ref.IDnm_002226.3) cDNA from nucleotide 
306 to 2171 was synthesised by GeneScript.  
The E. coli strain used to routinely transform plasmid DNAs during cloning procedures was DH5 
(genotype: fhuA2 lac(del)U169 phoA glnV44 Φ80' lacZ(del)M15 gyrA96 recA1 relA1 endA1 thi-1 
hsdR17) and the E. coli strains used for protein expression were BL21(DE3) (genotype: E. coli B F
–
 
ompT gal dcm hsdSB(rB
-
 mB
-
) λ(DE3)), BL21 Star (DE3) (genotype: E. coli B F
-
ompT hsdSB (rB
-
, mB
-
) 
gal dcm rne131 λ(DE3)) and SHuffle T7 Express (Lobstein, Emrich et al. 2012) (genotype: E. coli B 
fhuA2 lacZ::T7 gene1 [lon] ompT ahpC gal λatt::pNEB3-r1-cDsbC (Spec
R
, lacI
q
) ΔtrxB sulA11 R(mcr-
73::miniTn10--Tet
S
)2 [dcm] R(zgb-210::Tn10 --Tet
S
) endA1 Δgor ∆(mcrC-mrr)114::IS10).  
E. coli BL21 (DE3) and BL21 (DE3) Star competent cells were generated in-house from already 
existing bacterial strain stocks.  
II.1.1 Cloning in pET-47b(+) vector 
pET-47b(+) vector (Kan
R
), for expression in E. coli, was a kind gift from Colin E. McVey, PhD. 
Primers including a restriction enzyme recognition sequence were designed for each construct, as 
shown in Table II.1. For each construct, PCR amplification was carried out using 1.25 units of Pfu 
DNA polymerase, 0.2mM dNTPs and 0.2µM of each insert specific forward and reverse primers, 2-
10ng of template DNA and 1x polymerase reaction buffer. Amplification conditions were: 1 initial 
denaturing cycle at 95°C for 5 minutes, 32 cycles at 95°C for 30 seconds (denaturing step), 58°C for 
30 seconds (annealing step) and 72°C for 2 minutes (extension step)/ kb of amplicon, 1 final extension 
cycle at 72°C for 10 minutes. After amplification, insert size was confirmed by agarose gel 
electrophoresis, digested with 10 units of EcoRI and 10 units of HindIII for 1 hour at 37°C, and ligated 
into the destination vector, previously digested with the same restriction enzymes, under the same 
conditions, using 2.5 units of T4 DNA ligase and incubating overnight at 16°C. Ligation reactions were 
transformed into E. coli DH5 competent cells and plated in 2xYT agar plates supplemented with 
50µg/mL Kan. 
Colony PCR screening with Taq DNA polymerase with insert-specific primers was carried out with 
the same PCR conditions as for the initial amplification, to evaluate the presence of positive colonies. 
The colony PCR result was assessed by agarose gel electrophoresis of each PCR reaction. One 
positive colony for each clone was selected and incubated overnight at 37°C to saturation in liquid 
media (2xYT or PB) with 50µg/mL Kan. Plasmid DNA was isolated using GeneJET Plasmid Miniprep 
Kit according to the manufacturers' instructions. Plasmid DNA was further subjected to restriction 
                                                     
1 All reagents' catalogue numbers, suppliers, and buffer recipes are listed in Chapter VI- 
Appendix. 
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enzyme digestion to verify the presence of the insert and confirm the expected molecular sizes of both 
the insert and the vector. DNA fragments were analysed by agarose gel electrophoresis. Sequence 
integrity of each clone was confirmed by sequencing at STABvida, Portugal. 
 
Table II.1 - Primers used for Jag1, Jag2 and Dll1 cloning into pET-47b(+) bacterial expression 
vector. The nucleotide sequence for each primer is shown, highlighting the restriction enzyme sites 
in bold, the inserted stop codon in italic and the complementarity with the coding sequence in 
capital letters. 
Protein 
Target 
domain 
Restriction 
enzyme 
Primer Sequence 
hJAG1 
MNNL EcoRI 5'- gtgtgggaattcgggtCAGTTCGAGTTGG 
DSL EcoRI 5'- gagtatcagaattccGTGACCTGTGATGAC 
EGF3 HindIII 5'- gcaggcaagcttagcctaTTCACAGTTGG 
EGF9 HindIII 5'- gcagtaagctttcagttaTGAGCAGTTCTTG 
hJAG2 
MNNL EcoRI 5'- gtgcagaattcacgtCCGATGGGTTATTTTG 
DSL EcoRI 5'- ctgcagaattctGTTCGCTGCGATGAAAAC 
EGF3 HindIII 5'- cgtgcaggcaagcttcgcttaTTCACAGTTGC 
EGF9 HindIII 5'- cacggtaagcttggctaGCTACAGTTTTTAC 
hDLL1 
MNNL EcoRI 5'- ccttgaattctCAGGTCTGGAGCTC 
DSL EcoRI 5'- ctcaagaattcctaccgcTTCGTGTGTG 
EGF3 HindIII 5'- ctcgtcaagcttcagctaGCAGGTGGCACC 
EGF6 HindIII 5'- cgtcaagcttgtcctaACAGTGCCTCCC 
 
II.1.2 Cloning in pHL-sec vector  
pHL-sec vector (Amp
R
) (Aricescu, Lu et al. 2006), for mammalian expression, was a kind gift from 
Dr. Yuguang Zhao, through the application submitted to P-CUBE platform (Infrastructure for Protein 
Production Platforms, UE FP7). Primers including a restriction enzyme recognition sequence were 
designed, the forward with AgeI and the reverse with KpnI or EcoRV recognition sequences as shown 
in Table II.2. For each construct, PCR amplification was carried out using Pfu DNA polymerase as 
described above. Whenever necessary, primer annealing temperatures were optimized. After 
amplification, insert size was confirmed by agarose gel electrophoresis, digested with 10 units of AgeI 
and 10 units of KpnI or EcoRV. The destination vector was digested with AgeI and KpnI or with KpnI 
followed by Klenow fragment and then AgeI.  
Ligations were carried out using 2.5 units of T4 DNA ligase and incubated either one hour at RT 
or overnight at 16°C. Ligation reactions were transformed into E. coli DH5 competent cells and plated 
in 2xYT agar plates supplemented with 100µg/mL Amp. Colony PCR screening with Taq DNA 
polymerase with insert-specific primers was carried out to evaluate the presence of positive colonies. 
One positive colony for each clone was incubated overnight in liquid media with 100µg/mL Amp and 
plasmid DNA was isolated using GeneJET Plasmid Miniprep Kit. Plasmid DNA was further subjected 
to restriction enzyme digestion to verify the presence of the insert, and confirm the expected molecular 
sizes of both the insert and the vector; fragments were verified by agarose gel electrophoresis. DNA 
sequence integrity was confirmed by sequencing. 
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Table II.2 - Primers used for Jag1, Jag2 and Dll1 cloning into pHL-sec mammalian 
expression vector. The nucleotide sequence for each primer is shown, highlighting the restriction 
enzyme sites in bold and the complementarity with the coding sequence in capital letters. 
Protein 
Target 
domain 
Restriction 
enzyme 
Primer Sequence 
hJAG1 
MNNL AgeI 5'- ccaaggtgaccggtGCCTCGGGTCAGTTCG 
DSL AgeI 5'- gcatgatcaaccccaccggtCAGTGGC 
EGF3 KpnI 5'- gcaggcggtaccAGCAATTTCACAGTTGG 
EGF9 KpnI 5'- gctgcgggtaccGTCTTTCAGGTGTGAGC 
hJAG2 
MNNL AgeI 5'- gcactgaccggtCAGGCACGACGTCCG 
DSL AgeI 5'- atgatcaccggtGAAGACCGCTGGAAATCACTGC 
EGF3 KpnI 5'- cgggttagaggtaccGGCATGTTCCGC 
EGF9 EcoRV 5'- cgacaggcaccacccgatatCGGTTCACG 
hDLL1 
MNNL AgeI 5'- gtgtcagaccggtAGCTCTGGGGTGTTCG 
DSL AgeI 5'- cggtcggcaccggtTGGTCCCAGGACC 
EGF3 KpnI 5'- ggtgacactcggtaccCCCCAGCTCGC 
EGF6 KpnI 5'- gcgcaggtaccCTCGTTGTCGTCACAGTGC 
 
II.1.3 Cloning in pTT22SSP4 vector 
Cloning of hJagged1 domains MNNL-EGF9, human Jagged2 domains MNNL-EGF9 and human 
Dll1 domains MNNL-EGF6 and DSL-EGF6 was performed (as described in the previous section) in 
mammalian HEK expression vector pTT22SSP4 (Durocher, Perret et al. 2002), using NheI/BamHI 
sites. The primers designed to amplify the cDNA containing the restriction enzymes' recognition sites 
are listed in Table II.3. The resulting constructs were confirmed by sequencing (STABvida). 
 
Table II.3 - Primers used for Jag1, Jag2 and Dll1 cloning into pTT22SSP4 mammalian 
expression vector. The nucleotide sequence for each primer is shown, highlighting the restriction 
enzyme sites in bold, the inserted stop codon in italic and the complementarity with the coding 
sequence in capital letters. 
Protein 
Target 
Domain 
Restriction 
Enzyme 
Primer Sequence 
hJAG1 
MNNL NheI 5'- ccaaggtggctagcGCCTCGGGTCAGTTCG 
EGF9 BamHI 5'- gctgcgggatccttaTTTCAGGTGTGAGC 
hJAG2 
MNNL NheI 5'- gcactggctagcCAGGCAGCACGTCCG 
EGF9 BamHI 5'- cgacaggcaccacccggatccttaTCACG 
hDLL1 
MNNL NheI 5'- gtgtcaggctagcAGCTCTGGGGTGTTCG 
DSL NheI 5'- cggtcggcgctagcTGGTCCCAGGACC 
EGF6 BamHI 5'- gcgcaggatccttaGTTGTCGTCACAGTGC 
 
II.2. SDS-PAGE and Western Blot 
Samples were adjusted with SDS-PAGE Loading Buffer (1x final concentration) and boiled for 10 
minutes at 95°C; when needed, samples to be analysed in non-reducing conditions were adjusted with 
NuPAGE LDS sample buffer before SDS-PAGE analysis. 
SDS-PAGE was carried out using Criterion XT Precast Gels or Mini-PROTEAN TGX precast Gels 
using MES or MOPS as a Buffer system depending on number of samples to be analysed, and on the 
protein size. Gels ran at 200V for 35 or 45 minutes depending on MES or MOPS buffer system, 
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respectively, and were stained with SimplyBlue SafeStain according to manufacturers' instructions, or 
transferred to nitrocellulose membranes for further analysis. 
Polyacrylamide gels were transferred to nitrocellulose membranes using a Trans-Blot SD Semi-
Dry Transfer Cell apparatus (BioRad) according to manufacturer’s instructions: 25V for 45 minutes for 
large gels, and at 15V for 30 minutes for small gels, using NuPAGE Transfer Buffer. 
Membranes were blocked in 3% milk powder in PBS-0.05%T for 30 minutes, washed 3 times for 
5-10 minutes each in PBS-T, incubated with mouse α–His at 1µg/mL in PBS for 1 hour, washed 3 
times for 5-10 minutes each in PBS-T, incubated with α-mouse IgG-HRP at 2.5µg/mL in PBS for 30 
minutes and washed 5 times for 5-10 minutes each in PBS-T. Signal was developed with Western 
Lightning Plus-ECL Enhanced Chemiluminescence Substrate and images acquired in ChemiDoc 
(BioRad). 
 
II.3. Protein quantification 
Protein was quantified by Bradford assay with Bio-Rad Protein Assay Dye Reagent Concentrate. 
Samples were assayed in triplicate and the corresponding buffer was used for blank measurements. 
In a final volume of 1mL, 4µL of sample and 200µL Reagent were used. Blank-subtracted absorbance 
readings at 595nm were averaged and compared to a calibration curve prepared with BSA as a 
standard, with known concentrations. 
Alternatively, protein concentration was determined by spectrophotometic methods with 
NanoDrop taking in account the theoretical extinction coefficient and molecular mass calculated by 
ProtParam tool provided by ExPASy (available online at web.expasy.org/protparam/ ) with the input 
sequence for each protein and shown in Table III.1 and III.2 
 
II.4. Protein expression and purification using E. coli as host 
II.4.1 Small scale expression screenings 
Plasmids were transformed into competent cells and plated in 2xYT agar supplemented with the 
appropriate antibiotic(s). BL21 (DE3) and BL21 (DE3) star competent cells were transformed with the 
plasmid(s) of interest by electroporation, and transformation reactions were allowed to recover 1 hour 
at 37°C with 250rpm agitation; SHuffle
®
 chemically competent cells where transformed with the 
plasmid of interest by heat shock, and transformation reactions were allowed to recover 1 hour at 
30°C with 250rpm agitation. Of the transformation plates ten to fifteen colonies were picked and 
inoculated in 10mL expression media supplemented with the appropriate antibiotics, and cultures were 
grown to saturation overnight at 37°C and 250rpm. Cultures were diluted in the appropriate expression 
media (25mL) to an initial OD600 of 0.10-0.15 and allowed to grow at 37°C, or 30°C when using 
SHuffle
®
 strain, until the chosen OD600 for induction; cultures were induced with IPTG and induction 
proceeded at the chosen temperature and duration. For BL21 strains, the OD600 of induction was 
between 1.5 and 2.0, except when co-expression of the chaperone plasmid was desired. In this case, 
OD600 of induction was between 0.5 and 0.7, and co-expression was performed in the presence of 
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34µg/mL Cm, and chaperone plasmid was induced with 4mg/mL L-arabinose. A summary of the 
tested conditions for each protein construct are depicted in Table III.3. 
 
II.4.1.i Sample preparation for Induction and Solubility tests 
analysis 
Samples for each test condition of small-scale screenings were collected before and after 
induction. Samples were standardised by harvesting the culture volume corresponding to 2 OD600 
units. Cultures were centrifuged for 5 minutes at 13200xg at RT. Cell pellets corresponding to total 
protein before induction (NI) and total protein after induction (I) were resuspended in 1x SDS-PAGE 
Loading Buffer (Sambrook 2001). 
To evaluate the solubility of each condition, samples were lysed either by using BugBuster 
Protein Extraction Reagent (Novagen) following manufacturer’s instructions, home-made Lysis buffer 
with lysozyme and DNase for 15-30 minutes on ice, or Lysis buffer and three sonication pulses of 10 
seconds each. Soluble (Sol) and Insoluble (Insol) fractions were obtained by centrifugation at 16600xg 
for 30 minutes at 4°C. SDS-PAGE Loading Buffer (4x) was added to a final concentration of 1x.  
 
II.4.2 Protein expression and purification  
Large-scale protein expression was carried out in 2.5L TunAir flasks in the best conditions 
determined during the small-scale expression trials. Cells were harvested by centrifugation for 15 
minutes at 7500xg and 4°C, and cell pellet was stored at -80°C until processing. 
All chromatographic steps were performed using ÄKTApurifier or ÄKTAFPLC systems unless 
stated otherwise. All buffers were filtered through 0.22µm membranes and degassed. Reducing 
agents were added freshly before use and the pH was corrected to the final desired value. 
 
II.4.2.i Soluble fraction 
Cell pellets were thawed in Lysis Buffer (Sections VI.2.i, VI.2.ii) and the lysate was disrupted 
three times in a French Press at 10000 psi. The lysate was clarified by centrifugation for 35 minutes at 
48400xg, 4°C, and filtration through a 0.22µm filter. One 5-mL HisTrap column was connected to an 
ÄKTApurifier and equilibrated with 5 CV of MilliQ water and 5 CV of Buffer A. The sample was injected 
at 1mL/min and the column washed with 15 CV Buffer A, until baseline absorbance was below 
100mAU. Elution was carried out with a gradient 0-0.5M Imidazole in 10 CV, followed by 0.5-1M 
Imidazole in 4 CV. Eluted protein was collected in 2mL fractions. Fractions were analysed by SDS-
PAGE and WB. 
Fractions containing the protein of interest were buffer exchanged to HRV-3C reaction buffer 
using a HiPrep 26/10 desalting column and cleaved overnight with a GST tagged HRV-3C protease 
(produced and purified in-house) at 1:100 (w/w) ratio. Protein mixture was applied to a GSTrap column 
connected to a HisTrap column at 1ml/min and the flow-through was collected. Protein was 
concentrated and injected at 1ml/min to a HiLoad 16/600 Superdex 75pg (S75) column. Protein was 
16 
 
fractionated in 2mL fractions; fractions were loaded in a SDS-PAGE gel to confirm the presence of the 
protein of interest. 
 
II.4.2.ii Inclusion Bodies 
Test conditions for refolding were prepared based on extensive refolding studies (Rudolph and 
Lilie 1996). Inclusion bodies pellets were resuspended on ice in ressuspension / wash buffer, clarified 
by centrifugation for 10 min at 30000xg, 8°C, and the supernatant was discarded. This washing step 
was performed five times. A final wash was performed where Triton X-100 was omitted from the 
resuspension solution. The inclusion bodies were unfolded by dissolving the washed inclusion body 
pellets overnight at 4°C in solubilisation buffers containing (I) 6M Guanidine Hydrochloride, or (II) 8M 
Urea as protein denaturants, and clarified by centrifugation for 30 min at 30000xg, 8°C. Supernatant 
corresponding to the unfolded protein was analysed by SDS-PAGE and stored at -20°C until further 
use. 
Four Refolding Buffers were tested (Section VI.2.iii): 
 A - 200mM Tris, 3.7mM Cystamine, 6.5mM Cysteamine, 1M L-Arginine, pH 8.0; 
 B - 20mM Tris, 1mM EDTA, 1mM GSH, 0.1mM GSSG, pH 8.0; 
 C – Buffer A + 1M TMAO; 
 D – Buffer B + 1M L-Arginine and 1M TMAO. 
 
For protein refolding by rapid dilution, unfolded protein was added dropwise at 4°C to rapidly 
stirring Refolding Buffer at a final concentration of 0.1mg protein per millilitre of buffer, and incubated 
at 4°C for ~40h. The refolded mixture was then clarified by filtration through a 0.22µm filter to remove 
particulate matter, concentrated in Amicon device, and desalted in batch mode using PD-10 columns 
according to manufacturer’s instructions. Resulting samples were quantified by spectrophotometry and 
protein containing fractions were concentrated to ~1mg/mL in Amicon 10kDa MWCO. 
For large scale purification, a 2L culture was grown using the best condition determined before, 
centrifuged and lysed. Inclusion bodies were isolated and protein refolding was archived using the 
optimal conditions determined previously from the small scale purification results scaled accordingly. 
Refolded protein solution was clarified by centrifugation for 25 minutes at 30100xg at 4°C, followed by 
filtration through a 0.22µm pore membrane. Protein was concentrated using Amicon Stirred Cell unit 
and Amicon device. 
Size exclusion chromatography was performed in a S75 column connected to an ÄKTApurifier. 
Column was equilibrated with 1.5 CV of buffer (Section VI.2.iv) at 1mL/min, protein was injected at 
0.5mL/min and fractionated. Selected fractions were analysed by SDS-PAGE. 
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II.5. Protein expression and purification using HEK293 cells as 
host 
II.5.1 P-CUBE at UOXF, Oxford, United Kingdom 
II.5.1.i Small-scale expression screenings 
Adherent HEK293T cells were routinely cultured in DMEM supplemented with 10% FCS in a 95% 
air / 5% CO2 atmosphere at 37°C. Small scale screening experiments were performed by transient 
transfection of pHL-sec constructs in adherent HEK293T cells, plated in 6-well plates. For each 
transfection experiment, a cocktail consisting of plasmid DNA:transfection reagent complex was 
prepared by adding 8µL Lipofectamine2000 (1mg/mL) to 250µL serum-free DMEM, and 2 to 4µg 
plasmid DNA to 250µL serum-free DMEM. Both mixtures were briefly vortexed and combined in a 
single tube followed by incubation for 20 minutes at RT. The transfection cocktail was added to cells in 
DMEM + 2% FCS. Cell media was collected 48 hours post-transfection for Western Blot analysis of 
expression. 
 
II.5.1.ii Large-scale protein production 
Large scale transfection was performed in cells grown in expanded surface roller bottles under 
the same conditions as described above. For each roller bottle, a transfection cocktail containing 
0.5mg plasmid DNA and PEI to a DNA:PEI ratio of 1:2 was used. This was prepared by adding the 
pHL-sec DNA constructs to 50mL serum-free DMEM, mixing and adding 1mL PEI (1mg/mL). 
Transfection cocktail was incubated for 10 minutes at RT and, prior to adding to the cells, 0.375 mL 
Kifunensine (1mg/ml) was added to the mixture. Transfection cocktail with Kifunensine was added to 
cells in DMEM + 2% FCS, and incubated for 4 days. Media was harvested and clarified by 
centrifugation for 15 minutes at 4000rpm at 10°C, and filtration through a 0.22µm SteriTop-GP Filter 
Unit. Clarified media was concentrated 10 fold and partially buffer-exchanged to PBS using a 
QuixStand system by cross-flow filtration with hollow fiber cartridge of 10kDa MWCO, prior to 
purification. 
II.5.1.iii Protein purification 
Protein sample was purified in batch using Cobalt beads. Cobalt beads were extensively washed 
in distilled water followed by washing with PBS. Sample was mixed with the cobalt beads and 
incubated between 1 and 1 and a half hours at 16°C with 110rpm agitation. The bead:sample mixture 
was poured into a reusable glassware column and flow-through was collected. After all sample passed 
through, cobalt beads were washed with PBS, followed by a washing step of about 5 CV with wash 
buffer 1 (Section VI.2.v), and two washing steps of wash buffer 2 corresponding to about 3 and 2 CV, 
respectively. Protein was eluted with two steps of about 3 and 2 CV each of elution buffer. Eluted 
protein was concentrated in an Amicon 10kDa MWCO to a volume of 6mL. 
A HiLoad 16/600 Superdex 200 pg column connected to an ÄKTAexplorer was equilibrated with 
SEC buffer, and two 3mL injections were performed by direct load method in the sample loop. Eluted 
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protein was fractionated in 2mL fractions and analysed by SDS-PAGE with BenchMark™ Protein 
Ladder protein marker. 
 
II.5.2 Protein Expression performed at iBET/ITQB 
II.5.2.i Suspension cells 
Suspension culture adapted HEK293-EBNA cells were routinely maintained in FreeStyle F17 
media supplemented with 20mL/L Glutamax, 10mL/L Pluronic F-68 and 0.5mL/L Gentamycin in a 93% 
air / 7% CO2 atmosphere at 37°C with 110rpm agitation. Cells were sub-cultured twice a week with a 
starting inoculum of 0.3 to 0.4x10
6
 cells/mL. Suspension culture adapted HEK293T cells were 
routinely maintained in FreeStyle 293 media in a 95% air / 5% CO2 atmosphere at 37°C and 110rpm 
agitation. Cells were subcultivated and transfection procedures were performed as described above 
for HEK293-EBNA cells.  
 
II.5.2.ii Adherent cells 
Adherent HEK293T cells were routinely maintained in DMEM supplemented with 10% FBS in a 
95% air / 5% CO2 atmosphere at 37°C, and sub-cultured when reaching 85-95% confluency. For sub-
culturing, cells were rinsed once with PBS and dissociated with 0.05% Trypsin-EDTA for 5 minutes at 
37°C. Trypsin was inactivated by adding serum supplemented growth media. Optimal dilution for sub-
cultivation was determined by plating different dilutions of the obtained cell suspension, or different cell 
numbers so that sub-culturing was performed twice a week as previously described. 
 
II.5.2.iii  Small-scale expression screenings 
Small-scale expression screenings were performed by transiently transfecting 20mL suspension 
adapted HEK cells at 1.5-1.8x10
6
 cells/mL, grown for one passage in FreeStyle F17 with Glutamax 
media, with 0.5 or 1mg pHL-sec or pTT22SSP4 DNA constructs per Litre of culture, using PEI 
transfection reagent to a DNA:PEI ratio of 1:3. Transfection cocktails were prepared by adding the 
plasmid DNA to FreeStyle F17 media corresponding to 1/10th of the culture volume to be transfected 
and mixed. PEI reagent (1mg/mL) was added to the transfection cocktail and incubated for 10 minutes 
at RT prior to adding to the cells. Samples were collected 4 and 5 days post-transfection, and 
supernatant recovered for protein expression analysis by SDS-PAGE or WB as applicable. 
For adherent cells grown in 6-well plates, small-scale expression screenings were performed by 
transfecting 2 to 4µg pHL-sec plasmid DNA, using PEI as transfection reagent in a ratio DNA:PEI 1:3 
by adding the plasmid DNA to serum-free media, mixing, adding the PEI reagent and incubating for 10 
minutes prior to adding to the cells. Growth media samples were harvested 48 and/or 72 hours post 
transfection and analysed by SDS-PAGE or WB. 
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II.5.2.iv  Protein production 
A medium scale production was performed in the best condition obtained in the small-scale 
experiments, scaled up accordingly in a 3L Fernbach design erlenmeyer. A 1.5L culture of suspension 
adapted HEK293-Ebna cells was transfected with 1mg/L pTT22SSP4 DNA construct, PEI:DNA ratio of 
3:1 and harvested at 120hpt. 
 
II.5.2.v  Protein purification 
Harvested culture was clarified by centrifugation for 10 minutes at 9900xg, 4°C and the 
supernatant was recovered. Harvested media was further clarified by filtration through a 0.22µm 
VacuCap
®
 filter prior to injection in one 5mL-HisTrap column o/n with a peristaltic pump set to x10, 2. 
Injection was finished upon connection of the column to ÄKTApurifier. HisTrap column was washed 
with 5 CV of buffer A (Section VI.2.vi) and 5 CV of buffer B. Protein was eluted from the column in 
steps of 5, 10, 15, 20, 50 and 100% of buffer C. Selected fraction were analysed by SDS-PAGE. 
The fractions containing the protein of interest were pooled and concentrated using a stirred tank 
concentration unit with a 10kDa membrane. Protein mixture was injected in a S75 column, previously 
equilibrated with 1.5 CV of SEC buffer. Selected fractions were analysed by SDS-PAGE, pooled and 
concentrated. 
 
II.6. Differential Scanning Fluorimetry (DSF) 
DSF analysis was employed as a quality control of refolded protein, and used as a tool to 
evaluate the protein behaviour in different buffer compositions in several steps of protein purification. 
In a typical assay for quality control, a total volume of 20µL and a dye concentration of 5 fold were 
used to guarantee the best signal to noise ratio. The assays were prepared by adding 2.5, 5, 10 or 
20µg of protein, as applicable, to a final volume of 20µL of dye buffer solution, all prepared in the 
protein purification buffer. Fluorescence intensities versus temperature are used to calculate the 
protein melting temperature (Tm) by determining the first derivative (d(Rfu)/dT) to extract the exact 
transition inflection point. 
For the Buffer pH / salt screenings, a protein dye mixture was prepared in 25mM Hepes pH 7.5 
typically with 2µg protein, and dye 50x concentrated to a final volume of 2µl per well. This reaction mix 
was distributed in each one of the 96 wells of a low profile 96-well plate (Bio-Rad). Each buffer to be 
screened was added to a final assay volume of 20µl, thereby diluting the dye to 5x (assay 
concentration). 
The protein melting temperature (Tm) determination was performed by monitoring protein 
unfolding with the fluoroprobe SYPRO Orange dye, which although completely quenched in aqueous 
environment, emits fluorescence upon binding to protein hydrophobic patches. Such increase in 
fluorescence can be measured as a function of temperature. The thermal shift assay is performed on 
an iCycle iQ5 Real Time PCR Detection System (Bio-Rad), equipped with a charge-coupled device 
(CCD) camera, and a Cy3 filter with excitation and emission wavelengths of 490 and 575nm, 
respectively. This equipment can simultaneously detect the fluorescence changes in 96-well low 
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profile plates, and thus can be used for parallel thermal stability assays. The 96-well plates are sealed 
with optical quality sealing tape (Bio-Rad) and centrifuged at 2500xg for 2 minutes immediately before 
the assay to remove possible air bubbles. The plates are subsequently heated from 20 to 90ºC with 
stepwise increments of 1ºC with 10 seconds equilibration time, followed by the fluorescence read out. 
The results were analysed with iQ5 Optical System Software, version 2.1 and an Excel 
spreadsheet with automatic macros available in the group. This spreadsheet calculates automatically 
the Tm and generates normalised graphs for selected wells with the input of the raw values from the 
iQ5 program. 
 
II.7. Analytical Size Exclusion Chromatography 
A Superose 6 PC 3.2/30 column (GE) with a column volume of 2.4mL was equilibrated in 2 CV of 
milliQ water at 0.075mL/min, and 2 CV of protein buffer at 0.05mL/min. Samples were centrifuged for 
15 min at 16600xg, 4°C prior to direct loop injection at 0.05mL/min.  
 
II.8. Circular Dichroism (CD) spectroscopy 
CD spectra in the far-UV region (far-UV CD) were recorded from 205-260nm in a JASCO J-815 
spectropolarimeter. Acquisition parameters are as follows - accumulations: 10; data pitch: 0.2nm; 
scanning rate: 100nm/min; bandwidth: 2nm; sensitivity: standard (100mdeg); response time: 4 
seconds; temperature: 20°C. Protein buffer was used as blank for baseline corrections. Samples were 
freshly diluted in protein buffer to 0.2mg/mL and transferred to a 1cm path length quartz cuvette for 
spectroscopic analysis. 
Thermal ramp CD was performed with the following acquisition parameters - data pitch: 0.5°C; 
temperature slope: 2°C/min; bandwidth: 2nm; sensitivity: standard (100mdeg); response time: 2 
seconds; temperature range: 20-70°C, monitored wavelength: 222nm; protein sample concentration: 
0.2mg/mL. 
 
II.9. Protein Crystallization 
Protein crystallization experiments were performed in CrystalQuick™ 96 Well, Greiner (Hampton 
Research) using a Nano-Robot Cartesian Mini-Bee (Genomic Solutions, UK) for automated drop 
setup. Scale-up drops were performed in 24-well Cryschem Plate (Hampton Research) using sitting-
drop vapour diffusion method. 
For human Jagged2 DSL-EGF3 purified from inclusion bodies, besides the commercial screens, 
scale-up drops were performed with both protein pools based on the crystallisation condition published 
for human Jagged1 DSL-EGF3 (Cordle, Johnson et al. 2008): vapour diffusion method with reservoir 
solution composed by 8.5% PEG4000, 0.1M Imidazole Malate pH 7.0. A grid screen was also 
performed with combinations of 7.5%, 8.5%, 10% and 11% PEG4000 and 0.1 and 0.2M Imidazole 
Malate pH 7.0, with a 0.5:0.5 protein:crystallization solution ratio at 20°C. 
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Chapter III Results and Discussion 
III.1. Molecular Biology 
For each Notch Ligand protein in this study, human Jagged1, 
Jagged2 and Delta-like Ligand1, four constructs were designed 
spanning different domains, while maintaining the minimal binding 
region to the Notch receptor (DSL domain and EGF-like repeats 1 to 
3) as previously defined (Shimizu, Chiba et al. 1999). The construct 
names are abbreviated using the following nomenclature: starting in 
MNNL domain - M; in DSL domain - D; ending in EGF3 - E3; in 
EGF6 - E6, in EGF9 - E9, constructions depicted in Figure III.1. 
The constructs were designed and cloned successfully in the 
bacterial expression vector pET-47b(+) that presents an inducible T7 
promoter, bearing a N-terminal 6x Histidine tag and a HRV-3C protease cleavage recognition 
sequence, in frame with the 5’ end of the gene of interest. Construct boundaries and theoretical 
parameters for each construct are shown in Table III.1. 
 
Table III.1 - Theoretical Parameters calculated by ProtParam tool (ExPASy) for proteins 
expressed in pET-47b(+) vector. 
Protein Domains 
Construct 
Boundaries 
(a.a.) 
Molecular 
mass 
(Da) 
Extinction 
coefficient 
(M
-1 
. cm
-1
) 
Jagged1 
MNNL-EGF3 33 - 334 36378.5 61235 
MNNL-EGF9 33 - 561 61076.9 91905 
DSL-EGF3 185 - 334 19580.7 38400 
DSL-EGF9 185 - 561 44279.2 69070 
Jagged2 
MNNL-EGF3 26 - 345 38158.5 68225 
MNNL-EGF9 26 - 572 62154.2 95915 
DSL-EGF3 196 - 345 19661.8 38400 
DSL-EGF9 196 - 572 43675.5 66090 
Delta-
Like 
Ligand1 
MNNL-EGF3 18 - 325 36889.2 59745 
MNNL-EGF6 18 - 440 48908.5 69810 
DSL-EGF3 176 - 325 19476.6 36910 
DSL-EGF6 176 - 440 31486.0 46975 
 
The constructs were also cloned successfully in the mammalian expression vector pHL-sec 
(Aricescu, Lu et al. 2006). This vector has a CMV enhancer and a constitutive chicken beta-actin 
promoter, followed by a secretion leader peptide in frame with the 5’ end of the gene of interest. At the 
C-terminal there is a 6x Histidine tag sequence in frame with the 3’ end of the gene of interest. The 
constructs emcompassing the largest fragments for each protein, and the hDLL construct that showed 
the best expression profile at OPPF (Section III.3, page 52), were also cloned in the mammalian 
expression vector pTT22SSP4 (Durocher, Perret et al. 2002). pTT22SSP4 plasmid has a human CMV 
promoter followed by an intronic sequence. ORF starts with a signal peptide in frame with a 8x 
Histidine Tag and a TEV protease site, after which the gene of interest can be cloned using NheI 
Figure III.1 - Construct 
domain design. Each module 
represents one domain. EGF 
as blue and cbEGF in green. 
22 
 
restriction enzyme. Construct boundaries and theoretical parameters for each construct are shown in 
Table III.2. 
 
Table III.2 - Theoretical Parameters calculated by ProtParam tool (ExPASy) for proteins 
expressed in mammalian expression vectors. 
Protein Domains 
Construct 
Boundaries 
(a.a.) 
Molecular 
mass 
(Da) 
Extinction 
coefficient 
(M
-1 
. cm
-1
) 
Jagged1 
MNNL-EGF3 31 - 336 34986.9 59745 
MNNL-EGF9 31 - 565 59994.7 90415 
DSL-EGF3 166 - 336 20303.6 43900 
DSL-EGF9 166 - 565 45311.4 74570 
Jagged2 
MNNL-EGF3 22 - 350 37330.6 66735 
MNNL-EGF9 22 - 577 61368.4 94425 
DSL-EGF3 175 - 350 20948.3 42410 
DSL-EGF9 175 - 577 44986.1 70100 
Delta-
Like 
Ligand1 
MNNL-EGF3 21 - 328 34994.1 52755 
MNNL-EGF6 21 - 444 47147.5 62820 
DSL-EGF3 159 - 328 20166.3 43900 
DSL-EGF6 159 - 444 32319.8 53965 
 
III.2. Bacterial Expression 
III.2.1 Small-scale expression screenings with BL21 (DE3) strains 
The aim of the small scale expression screenings was to find the best conditions to express 
soluble Notch ligand proteins constructs using E. coli as host. For that purpose, different conditions 
known to affect soluble protein expression were tested such as: different host strains, growth media, 
induction OD600, time and temperature, IPTG concentration and the co-expression with molecular 
chaperones groEL and groES (encoded by the pGro7 plasmid, TaKaRa). Details of each particular 
expression screening are detailed in Section III.2, Table III.3. 
Since the only structural models available to date regarding Notch ligands are a short construct of 
human Jagged1 comprising domains DSL to EGF3 (Cordle, Johnson et al. 2008), and a smaller 
construct comprising exon 6 (Pintar, Guarnaccia et al. 2009), the first small-scale expression 
screenings performed were those using a similar construct from human Jagged2, as follows. 
 
III.2.1.i His6-human Jagged2 DSL-EGF3 
Since this construct was the first to be analysed, a comprehensive screening matrix was tested: 
two strains (BL21 (DE3) and BL21 Star (DE3)), two growth media (TB and PB), two IPTG 
concentrations (0.1 and 0.5mM), two temperatures and three induction durations (37°C for 2 and 4 
hours and 20°C o/n). Growth in the absence of IPTG was performed as a negative control. 
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Table III.3 - Summary of small-scale expression screenings for each construct. For each 
experiment, OD for induction, Induction temperature (T), time (t), concentration of inductor ([IPTG]), 
expression media, host strain and co-expression of pGro7 are indicated by (x). 
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The total protein extracts, corresponding to the test conditions shaded in green in Table III.3, 
were analysed by SDS-PAGE and the expected size for the protein (19.6KDa) is marked with a blue 
arrow in Figure III.2-A and -B. 
As one can observe, for hJag2 DE3 construct the small-scale screenings suggest that the best 
induction conditions are achieved when using BL21 (DE3) as host strain and PB as growth media 
(Figure III.2-A, right half of golden box). In this particular case, a similar intensity band is observed in 
all conditions where protein expression was induced, irrespective of IPTG induction concentration, 
time or temperature of induction. When using TB as growth media a band was also detected 
corresponding to the expression of the protein of interest, however the intensity is lower than that 
achieved when using PB as growth media (Figure III.2-A, left half of golden box). 
The results obtained when expressing this construct using BL21 Star (DE3) as host strain failed 
to deliver any positive result (Figure III.2-B, red rectangle). Neither of the tested conditions showed to 
have any expression of hJag2 DE3 upon induction since the band profile observed was similar to the 
non-induced control sample (comparing the lanes where IPTG concentration is 0 and 0.1 or 0.5mM). 
This result was surprising since the use of this strain had the purpose of augmenting recombinant 
protein expression. This strain has the rne131 mutation and the cells are defective on RNaseE, 
decreasing mRNA degradation throughout expression which enhances protein expression as the 
expression rate depends on mRNA stability (Sorensen and Mortensen 2005). Possibly the tested 
expression conditions using BL21 Star (DE3) as host strain were not the most suitable with the 
combination of media, induction OD and expression time for this particular construct. 
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A total absence of protein expression using BL21 Star (DE3) was not expected, but based on 
these observations the use of this strain was discarded for further studies.  
 
Figure III.2 - SDS-PAGE of the initial small-scale expression screening results for human 
Jagged2 DSL-EGF3. Panel A – expression using BL21 (DE3) as host strain; Panel B – expression 
using BL21 (DE3) Star as host strain. Growth media, Induction Temperature, IPTG concentration in 
millimolar and duration of induction in hours are indicated in the figure. Expected size of the protein 
of interest highlighted with the blue arrow on the right in both panels. Red rectangle in Panel B 
highlights the absence of expression using BL21 (DE3) Star as host strain. 
 
Bearing in mind the best results for protein expression for the human Jagged2 DSL-EGF3 
construct that were obtained using BL21 (DE3) as host strain and PB as growth media (as shown in 
Figure III.2-A), the best induction conditions for this construct were evaluated for protein solubility. 
BugBuster reagent was used to disrupt the cells, and the results were analyzed by Western Blot 
(Figure III.3). Western blot is a far more sensitive technique to allow for a more accurate evaluation of 
the ratio of soluble/insoluble protein of interest. 
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Samples taken from cultures after induction for 2 hours at 37°C show the highest percentage of 
soluble vs. insoluble protein of interest, more than the samples from cultures induced o/n at 20°C. We 
estimated about 10-fold more soluble protein by comparing the protein bands corresponding to the 
soluble fraction upon induction at 37°C compared to that at 20°C (Figure III.3). 
 
Figure III.3 - Western Blot analysis of the solubility tests for human Jagged2 DSL-EGF3 
construct using BL21(DE3) as host strain and PB as growth media. Epi-white image of the 
molecular markers was superposed to the chemiluminescence image acquired after 51 seconds. TI 
- Total induced sample, Sol - Soluble fraction, Insol - Insoluble fraction. The sample marked by a 
red asterisk was used as reference in Figure III.4 and Figure III.5. 
 
As one can observe in Figure III.3, only around 10% of the total protein of interest is soluble in the 
conditions tested so far. This result was not considered good enough to proceed for large scale 
production based on the conditions already obtained. Our results somewhat disagree with what is 
commonly reported, that induction with lower inducer concentration for longer periods of time at 
reduced temperatures increases protein solubility (de Marco, Vigh et al. 2005). It is possible that this 
hJag2 construct is toxic to bacterial cells, impeding their growth. It may also be the case that, upon a 
longer expression time, the protein concentration becomes higher than the bacterial cell can endure. 
Those reasons may reflect that most of the produced protein is stored in the form of inclusion bodies 
for cellular protection. Possibly, a shorter pulse of high expression rate can be resulting in a higher 
percentage of soluble protein for this hJag2 construct. 
As such, a new set of screenings was performed with the aim of improving protein solubility. To 
increase the soluble expression of our protein, co-expression of Jag2 construct together with the 
molecular chaperones groEL and groES encoded by pGro7 was pursued. Increased recombinant 
protein solubility can be achieved in the presence of groEL and groES co-expression with lower 
inducer concentrations as been reported previously (de Marco, Vigh et al. 2005). 
The conditions for these tests were based on previous optimizations, however the use of pGro7 
implies several alterations such as lowering the induction OD600 to 0.5-0.7 and adding L-arabinose as 
an inducer for chaperone expression. The influence of the lysis method in the percentage of soluble 
protein obtained while co-expressing the molecular chaperone was also evaluated using three lysis 
methods: BugBuster commercial reagent, a home-made lysis buffer supplemented with lysozyme and 
* 
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DNase and a combination of the lysis buffer and mechanical disruption by sonication. The results were 
analysed by SDS-PAGE and WB (Figure III.4). 
As one can observe in Figure III.4-A, all lysis conditions and methods tested were efficient in 
terms of cell lysis as we could obtain a wide range of soluble proteins. However, no intense band with 
the expected molecular weight of hJag2 DE3 (19.6kDa, Table III.1), indicated by the orange arrow, 
was detected; moreover, an intense band in all the insoluble fraction samples was observed with the 
expected size for hJag2 DE3, as indicated by the orange box. 
 
 
Figure III.4 - Expression and lysis conditions screening for human Jagged2 DSL-EGF3 co-
expressed with pGro7. Panel A – SDS-PAGE, Panel B – Western Blot, exposition time is 300 
seconds. Ref. stands for reference sample (marker with a red asterisk in Figure III.3). Orange 
arrows and box mark the expected size and the bands corresponding to this protein (19.6kDa, 
Table III.1). Samples are grouped according to fraction after lysis, soluble on the left and insoluble 
on the right, and lysis method as indicated in the figure. 
 
These observations are confirmed by the WB result in Figure III.4-B, where a protein band with 
the size corresponding to the His-tagged human Jagged2 DSL-EGF3 protein appears only for the 
insoluble fraction samples. As no protein was detected in the soluble fraction samples, no conclusions 
could be drawn from this result regarding the best conditions for obtaining soluble protein. However, 
when using the home-made lysis buffer supplemented with lysozyme and DNase we obtained the best 
lysis condition since the extracted proteins show a wider range in terms of molecular weight than the 
two other lysis methods employed. 
The Soluble fraction samples analysed in Figure III.4 were subjected to a second analysis by 
Western Blot, where a larger volume of sample was analysed in order to increase the total protein 
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amount per lane, and to allow evaluating more accurately the solubility profile of the tested expression 
and lysis conditions. The results are presented in Figure III.5. 
 
 
Figure III.5 - Western Blot analysis of soluble fraction samples from Figure III.4. Exposition 
time is 160 seconds. Ref. stands for reference sample (marker with a red asterisk in Figure III.3). 
Blue arrow marks the expected size for this protein (19.6kDa, Table III.1). 
 
The sample from Figure III.3, marked with a red asterisk (soluble fraction obtained when inducing 
expression for 2 hours at 37C with 0.1mM IPTG without co-expressing the molecular chaperones 
where about 10% soluble protein could be obtained) was used as reference sample for Figure III.5. 
The results obtained showed to be promising: protein expression under the conditions of induction 
with 0.1mM IPTG for 2 hours at 37°C and co-expression with the chaperone plasmid results in a 
higher amount of soluble protein (Figure III.5 – fuchsia box) compared to the protein previously 
obtained. Also, induction with lower concentration of IPTG also results in higher solubility in each 
induction time tested. This result is in agreement with the afore mentioned hypothesis that a short 
pulse of intense protein expression can increase the percentage of recoverable soluble protein. 
We could then estimate to obtain 20 to 25% soluble protein when inducing protein expression in 
the presence of the groEL and groES chaperones at 37°C for 2 hours with 0.1mM IPTG, and lysing 
the cells with the home-made lysis buffer supplemented with lysozyme and DNase (as there is a ~2 
fold increase in band intensity between the reference sample, previously estimated for 10% soluble 
protein, and the described condition). 
Therefore, we determined that for large-scale protein production and purification for this construct 
of human Jagged2 DSL-EGF3 we would use the following conditions: BL21 (DE3) host strain, PB as 
growth media, co-expression of the protein of interest with pGro7, induction of protein expression at 
OD600 0.5-0.7 at 37°C for 2 hours with 0.1mM IPTG and 4mg/mL L-arabinose followed by lysis with 
home-made lysis buffer. 
 
III.2.1.ii His6-human Jagged2 MNNL-EGF3, MNNL-EGF9 and DSL-EGF9 
In order to evaluate if there was a different construct of human Jagged2 that is amenable for 
expression of soluble protein, the remaining three hJagged2 constructs were expressed in an initial 
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small scale expression test based on the best expression conditions set for the human Jagged2 DSL 
to EGF3 construct reported above in Section III.2.1.i - Induction with 0.1mM IPTG at OD600 0.5 to 0.7 
for 2 hours at 37°C with co-expression of groEL and groES chaperones, using BL21 (DE3) and PB. 
The results were analysed by SDS-PAGE and WB (Figure III.6). 
In the SDS-PAGE analysis of hJagged2 constructs MNNL-EGF3, MNNL-EG9 and DSL-EGF9 
expression (Figure III.6-A) no soluble protein was detected. Nevertheless, the presence of the said 
proteins with the correct expected sizes could be observed in the lanes corresponding to the total 
induced and insoluble fractions. The Western blot analysis in Figure III.6-B confirmed the expression 
of the proteins with the correct sizes in the Insoluble fractions, and also showed that there was no 
soluble protein expressed, as expected by visualizing the SDS-PAGE in panel A. 
 
 
Figure III.6 - Initial small scale expression test for human Jagged2 constructs MNNL-EGF3 
(38.1kDa), MNNL-EGF9 (62.1kDa) and DSL-EGF9 (43.6kDa). Panel A – SDS-PAGE. Red dots 
mark the expected sizes for each construct; Panel B – Western Blot. Exposition time is 220 
seconds. NI – Non-induced culture; I – Total induced culture; In – Insoluble fraction; S – Soluble 
fraction. 
 
As such, a more comprehensive expression and solubility screening was performed for the 
human Jagged2 constructs bearing domains MNNL-EGF9 and DSL-EGF9 by testing different 
temperatures, times and IPTG concentrations, while maintaining BL21 (DE3), PB media and co-
expression with pGro7 (Figure III.7). We chose to pursue with these two MNNL-EGF9 and DSL-EGF9 
constructs of Jagged2 as they comprise more domains and could provide us more structural and 
biophysical information. 
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Figure III.7 - SDS.PAGE analysis of the small-scale expression screening for fine tuning for 
hJagged2 expression conditions. Results for hJagged2 MNNL-EGF9 indicated in black and for 
hJagged2 DSL-EGF9 in brown. Induction duration, temperature and IPTG concentration depicted 
above each condition. Purple and pink dashed rectangles mark the expected size of hJagged2 
MNNL-EGF9 and hJagged2 DSL-EGF9, respectively. NI – Non-induced culture; I – Total induced 
culture; S – Soluble fraction; In – Insoluble fraction. 
 
From the results presented in the SDS-PAGE in Figure III.7, no bands could be detected in the 
respective lanes of the soluble fractions for neither proteins in each test condition. These expression 
tests were performed with co-expression of pGro7 (enconding GroEL/ES molecular chaperones, with 
~60-65kDa), and the expression of these protein is observed in all analysed soluble fractions' lanes. It 
is especially evident in Fig. III.7-C the presence of two distinct bands in total induced fractions, 
corresponding to the molecular chaperones and hJagged2 MNNL-EGF9, but not in the lane 
corresponding to the soluble fraction. 
We could conclude however that the lysis efficiency was greater than in the previous tests since a 
broader range of proteins could be observed in the lanes corresponding to the soluble fractions 
(Figure III.6). The soluble fractions analysed by SDS-PAGE in Figure III.7 were subject to a more 
thorough analysis by Western Blot as shown in Figure III.8. 
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Figure III.8 - Western Blot analysis of soluble fractions from Figure III.7. Panel A – hJagged2 
MNNL-EGF9 (62kDA); Panel B - hJagged2 DSL-EGF9 (43.6kDa) (Exposition time is 300 seconds). 
Induction conditions and IPTG concentration (in millimolar) for induction as depicted above each 
lane. 
 
The results show that human Jagged2 MNNL-EGF9 (Figure III.8-A) was not expressed in any of 
the conditions tested in the soluble fraction, and the only observed band does not have the expected 
size for this protein (62kDa, Table III.1) but we cannot exclude possible proteolysis. The fact that 
neither of the conditions tested gave positive results for this protein construct could be due to its 
higher molecular weight and complexity. The higher complexity of Jag2 MNL-EGF9 protein, with 30 
predicted disulfide bonds (1 DSL and 9 EGF domains with 3 disulfides per domain), can be 
overwhelming for the cellular machinery causing not only translational stalling, but also can influence 
the redox potential of the bacteria's cytoplasm, aggravating the overall tendency of expressed protein 
insolubility, as observed for the previous constructs of human Jagged2. 
On the other hand, the results obtained for the human Jagged2 construct bearing domains DSL-
EGF9 (43.6kDa, Table III.1) showed to be promising with soluble protein expressed under induction 
with 0.1mM IPTG at 30°C for 4 or 6 hours as one can observe in Figure III.8. As such, the expression 
conditions chosen for a large scale expression for this construct were induction at OD600 0.5-0.7 with 
0.1mM IPTG for 4 or 6 hours at 30°C, using BL21 (DE3), PB media and co-expression with pGro7 
plasmid. 
 
III.2.1.iii His6-human Delta-Like Ligand1  
In order to assess the expression and solubility profiles for the human Delta-like Ligand1 
constructs, a small-scale expression screening based on our previous results was set up, with BL21 
(DE3), PB media, and protein induction at OD600 1.5-2.0 at 30°C for 6 hours or 18°C o/n with 0.5mM 
IPTG. The results are presented in Figure III.9. 
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Figure III.9 – SDS-PAGE analysis of human DLL1 constructs’ small scale expression 
screenings. Expression conditions are indicated above each set of four lanes. Red rectangles 
mark the expected sizes for each protein. NI – Non-induced culture; I – Total induced culture; In – 
Insoluble fraction; S – Soluble fraction. 
 
As one can observe in Figure III.9, all four constructs show good expression profiles: there is an 
evident band in the lanes corresponding to total induced extract (I, red rectangles), compared to the 
total non-induced extract (NI). However, in terms of solubility, the proteins were only detected in the 
insoluble fraction (Figure III.9, In). In all constructs, irrespective of induction condition tested, no clear 
band corresponding to the expected size of the proteins is seen in the soluble fraction by SDS-PAGE 
(Figure III.9, S). We therefore concluded that with the tested expression conditions little or no soluble 
protein could be obtained. Perhaps a Western blot analysis could reveal with greater detail the 
solubility profile of these constructs. Taking the knowledge that by that time we had acquired, we did 
not further analyse these samples. The purification tests of hJag2 DSL-EGF3 (Section III.2.3.i) and 
DSL-EGF9 (Section III.2.3.ii) constructs were performed prior to this analysis and we already had a 
hint that, without a visible band corresponding to the protein of interest as visualised by SDS-PAGE, 
there would be no interest in pursuing an expression condition that yields low amounts of soluble 
protein. 
 
In summary, we observe that although all the expression experiments using BL21 (DE3) strain 
can deliver good results in terms of total protein expression almost all the amount of the recombinant 
protein produced was insoluble and trapped into the inclusion bodies. 
 
III.2.2 Small-scale expression screenings with SHuffle® strain 
Since that the use of BL21 (DE3) strains as host for protein expression failed to fulfil the need of 
fair amounts of soluble protein amenable for protein purification, we sought for a modified strain 
capable of disulfide formation in E. coli cytoplasm as discussed in Chapter I. We chose SHuffle
®
 T7 
Express (Lobstein, Emrich et al. 2012) since this strain has both the advantages of E. coli cytoplasmic 
expression systems, combined with the cytoplasmic expression of periplasmic chaperones. Moreover, 
SHuffle
®
 has cellular reductases deletions that allow for a more oxidizing cytoplasmic environment 
tolerating disulfide bond formation in the cytoplasm, and it is adequate to use with T7 promoter-based 
vectors such as pET-47b(+). 
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As such, a simple small-scale screening was carried out using the conditions described by 
Lobstein, Emrich et al. (2012), where we tested the human Jagged2 constructs bearing the smaller 
and largest number of domains - DSL-EGF3 and MNNL-EGF9. The construct comprising domains 
DSL-EGF3 had been already extensively studied so it was screened using SHuffle
®
 as a quick control 
for changes in expression and solubility behaviour. The results are presented in Figure III.10. 
 
 
Figure III.10 - Small scale expression screenings for human Jagged2 MNNL-EGF9 (panel A) 
and DSL-EGF3 (Panel B) using SHuffle® as host strain. Induction conditions are depicted above 
each set of lanes. NI – Non-induced culture; I – Total induced culture; In – Insoluble fraction; S – 
Soluble fraction. Blue arrows point to the expected molecular weight for each protein. 
 
Using SHuffle
®
 strain as expression host we could obtain a good expression of both human 
Jagged2 constructs screened as there is an evident band in the total extracts of induced cultures (I) 
compared to the culture before induction (NI). Regarding solubility, it is again apparent for both 
constructs that no soluble protein could be produced. There could be several reasons for our results: 
the expression conditions used can be sub-optimal for SHuffle
®
 cells to properly form the disulfide 
bonds. Moreover, Lobstein, Emrich et al. (2012) concluded that this strain’s effect in disulfide bond 
formation in the cytoplasm is protein-specific, which may not be the case of this study. 
 
Taken together our results with both BL21 and SHuffle
®
 strains, we were not able to generate 
more than 20 to 25% estimated soluble protein. However we chose the human Jagged2 DSL-EGF3 
and DSL-EGF9 constructs to carry out purification trials of the protein available in the soluble fraction. 
 
III.2.3 Protein Purification from soluble fraction 
III.2.3.i Human Jagged2 - His6-hJAG2 DSL-EGF3 
Bacterial cell pellet of E. coli BL21 (DE3) expressing human Jagged2 DSL-EGF3 (19.6kDa, Table 
III.1) was lysed and the clarified soluble fraction (sample A) was injected in a HisTrap column 
connected to an ÄKTApurifier system. The insoluble fraction was stored at -80°C. The bound protein 
was eluted with a continuous gradient of imidazole and protein fractions were collected. 
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The elution chromatogram is showed in Figure III.11. One single protein peak was eluted with 
concentrations between 90 and 235mM imidazole. Fractions of the peak were analysed by SDS-
PAGE for the presence of hJag2 DSL-EGF3 (Figure III.12), and a protein pool consisting of fractions 7 
to 11 (right side of the peak) was desalted to HRV-3C protease cleavage reaction Buffer. Total protein 
was determined by Bradford Protein assay to be 9.53mg. 
 
 
Figure III.11 - Elution chromatogram of HisTrap column for the purification of human 
Jagged2 DSL-EGF3. Bound protein was eluted with a continuous gradient of Buffer B (in green, 
right vertical axis). Eluted protein was monitored by absorbance at 280nm and recorded (in blue, 
left vertical axis). The eluate´s fraction numeration is shown in red, in the bottom. 
 
After His-tag cleavage with HRV-3C protease, the protein mixture was separated in a tandem 
column setting consisting of a GSTrap column connected directly to a HisTrap column, allowing that 
both the protease (that was engineered to have a GST-tag), uncleaved protein and cleaved tag are 
separated from the untagged protein, which will not bind to the column and therefore will be collected 
in the flow-through. GSTrap and HisTrap columns were eluted and samples from each key step were 
analysed by SDS-PAGE to access cleavage efficiency (Figure III.13). 
As shown in Figure III.13, His-tag cleavage did not appear to be efficient as the percentage of our 
protein of interest in the purified cleaved protein sample was very low. As depicted in the figure, both 
uncleaved (Red dot) and cleaved protein (Green dot) are present in the samples corresponding to the 
tag cleavage reaction and the purified protein after cleavage. Moreover, there is also a large 
percentage of uncleaved hJag2 DE3 in the eluate of HisTrap column. 
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Figure III.12 - SDS-PAGE analysis of the fraction resulting from the first chromatographic 
step of hJag2 DE3 purification. Arrows point to the presence of hJag2 DE3 possibly in both 
monomeric (bottom arrow) and tetrameric (top arrow) forms. 
 
 
 
Figure III.13 - SDS-PAGE analysis of hJag2 DE3 His-tag cleavage with HRV-3C protease. Red 
dots mark uncleaved protein. Green dots mark cleaved protein 
 
As depicted in Figure III.12, the last analysed fraction still contains a great amount of our protein 
of interest. In order to assess if the target protein was also present in the remaining fractions of the 
first chromatographic step (eluted with high imidazole concentrations), western blot analysis was 
performed. As one can observe in Figure III.14 in fact, all the sampled fractions contained the protein 
of interest. 
36 
 
 
Figure III.14 - Western Blot analysis of the first chromatographic step of hJag2 DE3 
purification. All fractions of the chromatogram were sampled, except those already pooled in 
Sample B (see above in the text). 
 
Hence, since HRV-3C protease cleavage was not 100% efficient and the protein of interest was 
present in all eluted fractions of the chromatogram a second protein pool was prepared combining 
also the remaining fractions and the protein eluted from the HisTrap (see Figure III.13). This second 
protein pool was then subjected to the same procedure as Sample B, namely, desalting to HRV-3C 
protease cleavage buffer, protein concentration determination (428.4mg), tag cleavage overnight, and 
cleaved protein purification using the same column tandem setup described earlier. Flow-through was 
collected and the efficiency of this purification was accessed by SDS-PAGE and WB (Figure III.15). 
 
 
Figure III.15 - SDS-PAGE (Panel A) and WB (Panel B) analysis of second hJag2 DE3 His-Tag 
cleavage with HRV-3C protease. 
 
From the analysis of Figure III.15-A, it is clear that the second pool contains less protein of 
interest than the first pool (Figure III.13, lane 1), and therefore no intense band corresponding to 
hJag2 DE3 could be visualised by SDS-PAGE in neither samples therein analysed. However, the WB 
analysis of the same samples revealed the presence of the target protein in this second pool (Figure 
III.15-B, lane 1). We assumed here that the cleavage reaction was more effective than the previous 
one, since no protein band was detected by WB upon protease addition, namely in the tag cleavage 
reaction, in purified cleaved protein and HisTrap elution samples (Figure III.15-B). Still, the protein 
mixture contained several contaminant proteins. 
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The protein mixture was concentrated and injected in a SEC column in order to separate our 
protein of interest from the remaining contaminants. The resulting chromatogram is shown in Figure 
III.16. Selected fractions were analysed by SDS-PAGE (Figure III.17). 
 
 
Figure III.16 - Size Exclusion Chromatogram of hJag2 DSL-EGF3. Injection is marked in pink 
and volume was corrected to zero at that point. Protein was monitored by absorbance at 280nm 
and recorded (in blue, left vertical axis). The eluted fraction numeration is shown in red, in the 
bottom. 
 
 
Figure III.17 - SDS-PAGE analysis of SEC fractions for the purification of human Jagged2 
DSL-EGF3. Red arrow marks the expected size for human Jagged2 DSL-EGF3 after tag removal 
(17.6KDa). 
 
Rationalizing the chromatogram with the SDS-PAGE in Figure III.17, the first peak corresponds to 
the proteins not resolved by this column, i.e., proteins with higher molecular weight than the upper limit 
of resolution for this column; the broad peak corresponds to an unresolved mixture of lower molecular 
weight proteins (Figure III.17, fractions 17 to 29). We conclude that all lanes have multiple proteins 
and no intense band corresponding in the expected size for human Jagged2 DSL-EGF3 protein, which 
is 17.6kDa after tag removal, was evident by SDS-PAGE analysis (Figure III.15, lane 3 and Figure 
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III.17, lane 1). It would have been crucial to finish the first chromatographic step with a more pure 
sample in order to facilitate the identification of our protein of interest by SDS-PAGE following the SEC 
step. Moreover, in Figure III.17 any of the myriad of bands could point to the presence of different 
oligomers as one may find bands corresponding to the expected size of dimers, trimers and tetramers. 
 
Therefore, a new purification strategy was pursued, using the inclusion bodies from the 
expression experiments since, by observing the western blots from Figure III.3 and Figure III.4, a large 
portion of the protein remains insoluble after lysis when expressed using the stated conditions. 
 
III.2.3.ii Human Jagged2 - His6-hJAG2 DSL-EGF9 
Bacterial cell pellet of E. coli BL21 (DE3) expressing human Jagged2 DSL-EGF9 (43.6kDa, Table 
III.1) was lysed and the clarified soluble fraction (sample A) was injected in a HisTrap column. The 
bound protein was eluted with steps of imidazole corresponding to a 2% increase in Buffer B in each 
step between 70 and 210mM imidazole. Afterwards, a continuous gradient was applied between 210 
and 500mM imidazole in 10 CV, and between 500 and 1000mM imidazole in 2 CV. Eluted protein 
fractions were collected (Fig. III.18). 
For this purification, the elution was performed with steps rather than a gradient in order to 
achieve a better protein separation in this first chromatographic step as discussed in the previous 
section for human Jagged2 DSL-EGF3 purification. We opted for 20mM imidazole steps in order to 
generate, by discrete increments in imidazole concentration, a fine-tuned elution profile. Several peaks 
were eluted with each step of increasing concentration of imidazole. Fractions corresponding to each 
peak were analysed by SDS-PAGE and WB for the presence of hJag2 DE9 protein (Fig. III.19). 
 
 
Figure III.18 - Elution Chromatogram from HisTrap column for the purification of human 
Jagged2 DSL-EGF9. Bound protein was eluted with a combination of steps with increasing 
concentration and a continuous gradient of Buffer B (in green, right vertical axis). Eluted protein 
was monitored by absorbance at 280nm and recorded (in blue, left vertical axis). The numeration of 
the analysed fractions is shown in red, in the bottom. 
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As one can observe in Fig.III.19, no band with the expected molecular mass for hJag2 DE9 
(43.6kDa, Table III.1) is evident neither by SDS-PAGE (Panel A) or WB (Panel B) analysis. The SDS-
PAGE analysis reveals low molecular weight contaminants spread in all tested fractions and one 
100kDa protein in fractions 17 to 29, corresponding to two consecutive peaks, eluted with 90 and 
110mM imidazole, respectively. Moreover, the WB analysis reveals the presence of multiple proteins 
throughout the analysed fractions. Those proteins are not visible in the SDS-PAGE analysis, and most 
likely are those E. coli contaminants that also react with anti-His-tag antibody besides interacting with 
the HisTrap column. 
The possibility that our protein could be forming stable oligomers was discarded as in Fig. III.19-B 
there is not a positive band for His-tagged proteins corresponding to any possible size of hJag2 DE9 
as a monomer or oligomer. Therefore, we concluded that a new strategy design to produce and purify 
this protein was also needed as for the purification of human Jagged2 DSL-EGF3. 
 
 
Figure III.19 - Analysis of the HisTrap Chromatographic step fractions for hJagged2 DSL-
EGF9 (44kDa). Panel A - SDS-PAGE; Panel B - WB, exposition time is 240 seconds. Blue arrows 
mark the expected size for this protein. I - Injected sample, FT - Flow-through, W - Wash, Numbers 
correspond to fraction numbers in the chromatogram in Fig. III.18. 
 
III.2.4 Purification of His6-hJAG2 DSL-EGF3 from inclusion bodies 
Inclusion bodies are frequently formed upon recombinant protein expression in E. coli. These 
inactive protein aggregates accumulate in the bacterial cells due to the high metabolic burden of 
recombinant protein expression and/or due to toxicity issues. Several studies were conducted using 
model proteins for in vitro refolding studies, but highly disulfide-bonded protein still pose enormous 
challenges (Rudolph and Lilie 1996). In this article, the authors go through the parameters affecting 
both inclusion body solubilisation and refolding such as the use of different reagents. The strategy 
followed was to purify the His6-hJAG2 DSL-EGF3 from inclusion bodies. The protocols followed were 
based on that information and in the protocols by Marko Hyvonen's group (University of Cambridge, 
Department of Biochemistry), available online (http://www-cryst.bioc.cam.ac.uk/groups/hyvonen/ 
methods, February 2013). In search for the best refolding conditions for this protein construct, several 
different solubilisation (GuHCl and Urea) and refolding (oxido-shuffling pairs, buffer strengths, 
additives) reagents were tested (see Section II.4.2.ii for the exact conditions). 
 
40 
 
III.2.4.i Small-scale refolding tests 
The small-scale expression tests for human Jagged2 DSL-EGF3 construct (Figure III.3; Figure 
III.4) showed that a large portion of the produced protein is insoluble. Therefore, the insoluble fraction 
was used for the initial inclusion bodies solubilisation and refolding tests. We used two of the most 
used solubilisation agents, GuHCl and Urea and two oxido shuffling pairs GSH/GSSH and 
cysteamine/cystamine (Rudolph and Lilie 1996). Also, L-arginine was included in the refolding buffers 
to evaluate if its presence could improve refolding and prevent the formation of non-soluble 
intermediates (Chen, Liu et al. 2008). 
Two denaturation agents in a buffered solution, and four Refolding Buffers were tested, as 
mentioned previously in Section II.4.2.ii, to a total of eight different test conditions, summarised here 
briefly in the purpose of contextualisation: 
 
 (I) – 6 M Guanidine Hydrochloride, 
 (II) – 8M Urea; 
 A – 200mM Tris, 3.7mM Cystamine, 6.5mM Cysteamine, 1M L-Arginine, pH 8.0, 
 B – 20mM Tris, 1mM EDTA, 1mM GSH, 0.1mM GSSG, pH 8.0, 
 C – Buffer A + 1M TMAO, 
 D – Buffer B + 1M L-Arginine and 1M TMAO. 
 
After solubilisation, protein was quantified by UV spectrophotometry in Nanodrop using the 
determined theoretical extinction coefficient (Table III.1). The process of inclusion bodies isolation and 
solubilisation was assessed by SDS-PAGE and the purification and solubilisation of inclusion bodies 
was considered to be successful with both GuHCl and Urea (Figure III.20). 
 
Figure III.20 - SDS-PAGE analysis of human Jagged2 DSL-EGF3 inclusion bodies isolation 
and purification steps. 
 
The refolding conditions were prepared as described in Chapter II, Section II.4.2.ii using two 
oxido shuffling systems, reduced and oxidised glutathione GSH-GSSH (Pintar, Guarnaccia et al. 
2009) and cystamine-cysteamine pairs. The presence of protein precipitation was clearly observed 
immediately after setting up and during the refolding experiment duration. All refolding solutions 
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appeared to be cloudy, indicative of protein precipitation occurring during the refolding process. 
Refolding solution B with protein solubilised with GuHCl (Shimizu, Chiba et al. 1999) and refolding 
solution C (IC and IIC) appeared to cause more protein precipitation. 
After refolding, protein solutions were clarified by centrifugation, desalted using PD-10 disposable 
columns and protein concentration was determined by spectrophotometry (Table III.4 §). The fractions 
containing protein were pooled and concentrated using Amicon concentrator devices, and protein 
concentration was determined by Bradford Protein Assay (Table III.4 ¤). Refolding conditions (I)B and 
(II)C showed no protein in the quantification and were not further analysed. Remaining protein 
samples obtained after refolding were analysed by SDS-PAGE (Figure III.21) and all presented >90% 
purity.  
 
 
Figure III.21 - SDS-PAGE of refolded human Jagged2 DSL-EGF3 in each refolding condition. 
I - Denaturation of inclusion bodies in GuHCl containing buffer; II - Denaturation with Urea 
containing buffer; A - Refolding with cystamine-cysteamine pair and arginine; B - Refolding with 
GSH-GSSG; C - Refolding as in A supplemented with TMAO; D - Refolding as in B, supplemented 
with arginine and TMAO. 2ug of each protein sample was applied in the gel. 
 
To assess if the refolding process was successful, Differential Scanning Fluorimetry (DSF) 
assays were performed. DSF allows the determination of the protein's melting temperature (Tm) by 
monitoring protein thermal unfolding and requires minimal amounts of protein. The thermal 
denaturation curves for each assay were analyzed, and the melting temperatures determined by the 
calculation of the first derivative, which corresponds to the midpoint temperature of the cooperative 
protein-unfolding transition. We employed this strategy for the reason that if the refolding process was 
successful, our protein of interest would be folded and would probably show a signal in the DSF. 
The DSF result (Figure III.22) shows that human Jagged2 DSL-EGF3 purified from inclusion 
bodies, solubilised with GuHCl and refolded with Buffer D (20mM Tris, 1mM EDTA, 1mM GSH, 0.1mM 
GSSG, 1M Arginine, 1M TMAO, pH 8.0) was the only protein sample where thermal denaturation 
yielded Tms (around 50°C). However, protein refolded in Buffer A and C with protein extracted from 
inclusion bodies solubilised with GuHCl generated low intensity denaturation curves (Figure III.22-A in 
green and -B in light blue). In all denaturation curves obtained, one can notice that the first reading 
corresponds to the maximum fluorescence value obtained, suggesting that all the protein samples 
have denatured protein. 
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Figure III.22 - DSF analysis of human Jagged2 DSL-EGF3 refolded from Inclusion Bodies. 
Thermal denaturation curves, normalised such as the highest value corresponds to 1 and the 
lowest value to zero. Panel A - Protein solubilised with GuHCl and Urea and refolded in Refolding 
Buffer A; Panel B - Protein solubilised with Urea and refolded in Refolding Buffer B, Protein 
solubilised with GuHCl and refolded in Refolding Buffer C; Panel C - Protein solubilised with GuHCl 
and Urea and refolded in Refolding Buffer D (see appendix for buffer composition). 
 
The results obtained for the small-scale refolding tests are summarised in Table III.4. 
 
Table III.4 - Summary of refolding tests for human Jagged2 DSL-EGF3. 
Solubilisation 
Buffer 
Solubilised 
Protein 
Refolding 
Buffer 
Precipitation 
during refolding 
Refolded 
protein (µg) 
§             ¤ 
DSF 
readout 
GuHCl (I) 
37.4mg; 
22mg/mL 
A ++ 1060 824 # 
B ++++ 
*
 n/a n/a n/d 
C +++ 357 88 # 
D ++ 107 101 Yes 
Urea (II) 
66.9mg; 
35.22mg/mL 
A + 448 222 No 
B +++ 229 170 No 
C ++++ 362 n/a n/d 
D + 369 231 No 
n/a - not applicable; n/d - not determined; § - initial protein quantity determination; ¤ - final protein 
quantity determination; * - all protein precipitated in the refolding experiment; # - only one triplicate 
with denaturation curve in the DSF experiment. 
 
We found that when using Urea in the solubilisation buffer more protein could be extracted from 
the inclusion bodies (66.9mg) when compared to Guanidine Hydrochloride (37.4mg). Regarding the 
results obtained when using GuHCl as denaturation agent, the amount of protein obtained after 
refolding with Refolding solution A was the highest, rendering 1060 and 824µg. Nevertheless, human 
Jagged2 DSL-EGF3 refolded under this condition failed to generate denaturation curves in the DSF 
assay, indicating that either no folding was aquired, or that protein was not stable. Using condition (I)C 
produced the same outcome as (I)A in the DSF result, apart of giving much less protein. On the other 
hand, and altough yielding less protein at the first quantification, the output of Refolding condition (I)D 
was the only protein sample that generated denaturation curves, consistently, in all triplicates of the 
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DSF assay. This was also the only protein sample that whitstand during the buffer exchange and 
concentration steps, having minimal (~5.5%) losses. All protein samples obtained after refolding urea-
solubilised protein failed to generate denaturation curves in the DSF assay, regardless of the fact that 
more protein could be solubilised in the start of the process. 
As the buffers used for the refolding assays were based on the conditions for other proteins 
(reviewed by Rudolph and Lilie (1996) and in the protocols from Hyvonen's group) and may not be the 
best suited for our protein, we tested the influence of different buffers and salt concentrations on its 
the denaturation profile by DSF. DSF-based buffer screens have been used for identify buffer 
formulations that stabilize proteins (for example for structural studies (Ericsson, Hallberg et al. 2006, 
Santos, Bandeiras et al. 2012)). The protein sample that presented denaturation curves in DSF (ID, 
Figure III.22-C) was used to perform a screen where different buffer formulations with pH values 
between 5.0 and 10, in combination with four different salt conditions were tested in a 96-well plate 
format (Section VI.3, Table VI.2). The theoretical Isoelectric Point (pI) for this protein is 5.82 
(calculated with ProtParam Tool online), and the overall protein solubility tends to increase with higher 
solvation; hence, 74 buffer-salt conditions were tested. A first reference assay with 25mM Hepes, pH 
7.5 was set up, as this buffer shows to have the least pH variation upon heating, and a second 
reference with the protein’s buffer was also used. In Figure III.23 the best curves are presented. 
 
 
Figure III.23 - DSF Buffer Screen result for refolded hJag2DE3. The represented curves were 
chosen according to the parameters stated in the text. hJag2 DE3 Tm is also shown. Sodium / 
Potassium Phosphate pH 7.0, 150mM KCl, in orange, was chosen as the protein buffer. 
 
There were several factors to consider while analysing the results: the initial fluorescence, the 
intensity of the denaturation curves, corresponding to the overall availability of protein to denaturate, 
the sharpness of the first derivative curve and the relative increase in Tm compared to the reference 
sample. 
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As one can observe, Sodium / Potassium Buffer is represented in five of the tested conditions 
showing a positive effect on the stability of human Jagged2 DSL-EGF3. Moreover, this buffer system 
at pH 7.0 seems to increase hJag2 DSL-EGF3 stability as, regardless of salt conditions, the curves in 
light blue, green and orange shown in Figure III.22 have a higher Tm shift compared to the reference 
curve, in blue. These buffer/salt conditions are increasing the protein's stability as observed by the Tm 
increase. We chose to pursue a large scale protein purification and refolding using Sodium / 
Potassium Buffer pH 7.0 with 150mM KCl (Tm = 58°C) in the composition of all buffers used. 
III.2.4.ii Large scale refolding and purification of His6-hJAG2 DSL-
EGF3 
Inclusion bodies were isolated from 2L culture volume, (expressed in the best conditions 
determined for the highest protein expression as in Sections II.4.2.i and III.2.1.i), solubilised in 
Solubilisation Buffer and protein was quantified by spectrophotometry (55.99mg/mL, 587.93mg total). 
The purity of the preparation was estimated by SDS-PAGE to be 95% (Figure III.24-A). Protein was 
refolded by rapid dilution to 0.125mg/mL in Refolding Buffer for 40 hours at 4ºC. subsequently, a 50-
fold concentration step was followed and protein concentration was determined by Bradford assay to 
be 1.1mg/mL, yielding 105.7mg total protein. Refolded protein was desalted and protein concentration 
was determined by NanoDrop to be 0.480mg/mL, 69.57mg total, confirming a loss of around 30% of 
total protein.  
 
Figure III.24 - Evaluation of human Jagged2 DSL-EGF3 Large-scale purification from 
inclusion bodies. Panel A - Isolation and Solubilisation steps; Panel B - Refolded protein after the 
desalting step. 
 
Protein stability was evaluated by DSF, as before (Figure III.25). Surprisingly, the obtained Tms in 
this assay are comparable to those obtained previously (49, 50 and 53°C in the small scale test and 
48, 51 and 52°C in this large-scale purification). However, the initial fluorescence intensity was in this 
case lower, suggesting the presence of less denaturated protein in solution, and in agreement the 
denaturation curves are more intense indicating the presence of more properly folded protein in 
solution. Thus, comparing the overall DSF results, the applied modifications in buffer formulation may 
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have improved the refolding process. Nevertheless, the initial fluorescence was still a matter of 
concern and the obtained Tm values could be improved, thus a DSF Buffer and Salt screen was 
performed (Figure III.26). 
 
 
Figure III.25 - DSF evaluation of hJag DE3 protein after refolding. The thermal denaturation 
curve represents one triplicate of the assay. 
 
As in the previous DSF buffer screen, the best buffer for our target protein is Sodium/Potassium 
Phosphate in which the protein showed the best denaturation curves and the highest Tm. Jagged2 
stability was also shown to be salt dependent, with the preferred salt conditions to be 500mM NaCl, as 
there is a clear shift of 2°C, compared to lower salt concentrations assayed. 
 
 
Figure III.26 - DSF buffer screen result after large scale refolding of human Jagged2 DSL-
EGF3 from inclusion bodies. The best thermal denaturation curves are shown, chosen with the 
previously described criteria. 
 
As such, the protein buffer was exchanged for Sodium /Potassium Phosphate, 300mM NaCl, pH 
7.0. We decided to lower the salt concentration for the sake of crystallisation experiments (discussed 
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below). Also, envisioning the crystallisation trials, there was the need to assure that the protein sample 
was monodisperse. 
For those reasons, a SEC was performed with the optimized buffer and therefore both 
requirements would be accomplished simultaneously (Fig. III.27). Two injections were performed, 
corresponding to 16.6mg of protein, and showing a similar elution profile. According to the calibration 
curve, the estimated molecular masses corresponding to the obtained elution volumes were 73.3, 
38.2, 18.6 and 6.9kDa, respectively. The peak assigned to have 18.6kDa most likely corresponds to 
hJag2 DSL-EGF3 (19.6kDa, Table III.1). Nevertheless, fractions corresponding to all the peaks were 
analysed by SDS-PAGE (Figure III.28). 
 
 
Figure III.27 - Size Exclusion Chromatogram for the purification of human Jagged2 DSL-
EGF3 from inclusion bodies. Injection is marked in pink and volume was corrected to zero at that 
point. Protein was monitored by absorbance at 280nm and recorded (in blue, left vertical axis). The 
eluted fraction numeration is shown in red, in the bottom. 
 
As one can observe in the SDS-PAGE (Figure III.28), the first and second peaks (fractions 7 to 
21) correspond to high molecular weight contaminants; the third peak (27-34) corresponds indeed to 
our protein of interest but surprisingly, the fourth peak also corresponds to hJag2 DE3 (fractions 37 to 
54). Since both peaks contain the protein with a high degree of purity but were eluted separately, two 
pools were prepared and treated separately thereafter - the third SEC peak was termed Pool 1 and 
the fourth Pool 2. 
The fact that Jagged2 may adopt a pencil-like shape, as for Jagged1 structural data presented by 
Cordle, Johnson et al. (2008), can explain why both protein peaks contain our target protein with 
elution volumes so discrepantly different than those calculated for globular proteins. We hypothesize 
that Pool1 may correspond to a dimeric and Pool2 to a monomeric form of Jag2 DE3. 
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Figure III.28 - SDS-PAGE analysis of the SEC fractions for the purification of human Jagged2 
DSL-EGF3 from inclusion bodies. Sampled fractions are marked with the respective numbers on 
top; bottom lines delimit each of the four peaks obtained in the chromatogram from Fig. III.27. 
 
Both protein pools were concentrated and protein quantified by Bradford assay. Pool1 was 
concentrated to a final volume of 87µL and protein concentration was determined to be 7.5mg/mL, 
0.63mg total; Pool2 was concentrated to a final volume of 733µL and protein concentration was 
determined to be 7.9mg/mL, 5.7mg total. 
 
The results obtained for the of hJag2 DSL-EGF3 large scale protein refolding and purification are 
summarised in Table III.4. 
 
Table III.4 – Summary of hJagged2 DSL-EGF3 Large Scale Protein Refolding and 
purification. 
 
Volume 
(mL) 
Quantity 
(mg) 
Concentration 
(mg/mL) 
Loss 
(%) 
Initial Refolding Solution 4500 560 0.125  
Final, Clarified Refolding Solution 95 105.7 1.11 81.1 
Refolded Protein after Buffer exchange 145 69.57 0.48 34.2 
Concentrated Protein Prior to SEC 24 56.96 2.37 18.1 
Resulting Protein Pools from SEC of 16.6mg n/a 10.14 n/a 38.9 
Resulting Pool 1 0.42 2.30 5.5 77.3 
Concentrated Pool 1 0.087 0.63 7.5 72.6* 
Resulting Pool 2 2.80 7.84 2.8 22.68 
Concentrated Pool 2 0.733 5.7 7.9 27.3* 
* - Relative to the obtained protein sample 
 
In order to determine the differences between both protein pools obtained in the SEC, DSF 
(Figure III.29), analytical SEC (Fig. III.32) and CD analysis were employed. Circular dichroism spectra 
unveils protein secondary structure elements in solution. Both tested hJag2 DE3 protein pools showed 
no signal significantly different from the baseline as well as no thermal ramp denaturation profile, 
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possibly indicating that the protein samples did not contain measurable amounts of secondary 
structure elements. The results are therefore not presented. 
As one can observe in Figure III.29-A, pools 1 and 2 have significantly different melting 
temperatures, 56 and 67°C on average, respectively. Also, the curve intensities are incredibly 
disparate (Figure III.29-B). These facts corroborate that there must exist differences between the two 
protein pools in terms of structural elements and percentage of folded protein that can account for 
both the different melting temperatures and curve intensities. 
 
 
Figure III.29 - DSF analysis of pure human Jagged2 DSL-EGF3 protein after SEC from the 
inclusion bodies purification. Panel A - Normalised curves, Panel B - Non-normalised curves. 
Curve colour code is the same for both panels. 
 
In order to further characterise the protein pools and understand the differences observed in the 
DSF, an SDS-PAGE with both reduced and non-reduced samples was performed. For a non-reducing 
SDS-PAGE, the sample is prepared without reducing agent and boiling, in a SDS rich environment, 
allowing the peptide chains to be charged negatively and therefore separated based on the molecular 
mass, while maintaining the disulfide bonds. As one can observe in the SDS-PAGE (Figure III.30), the 
non-reduced protein samples show an apparently lower molecular weight in the non-reducing 
conditions than in the reducing conditions. This can be due to the more compact conformation 
imposed by the disulfide bonds in the non-reduced samples, compared to the denatured peptide chain 
in the reduced samples (Figure III.30, NR and R, respectively). The protein from the inclusion body 
solubilisation shows one single band whereas the protein sample injected in the SEC column, after the 
refolding, has two. This can possibly indicate that we are in the presence of mixed protein populations 
after refolding (possibly refolded with different combinations of disulfide pairs), or this double band can 
represent protein degradation products. Respecting the obtained protein pools after SEC, it is very 
clear that Pool 2 has two distinct bands, clearly indicative of, at least, two distinct protein populations, 
possibly with different arrangements in the disulfide bonds. Pool1 does not show the apparently higher 
molecular weight band as Pool2, but seems to have two bands as well. 
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Figure III.30 - SDS-PAGE analysis of the hJag2 DE3 refolding and purification process. 
Bacterial cell expression (Expr.), Inclusion body purification (IB (GuHCl)) and SEC – Injected (Inj. 
S75) and resulting protein samples (Pool 1 and Pool 2) were analysed in reduced (R) and non-
reduced (NR) environment. 
 
Similarly to human Jagged1, Jagged2 has twelve predicted disulfide bonds in DSL to EGF3 
domains (Figure I.3), which seem to be important in maintaining its folding and structure. Reducing 
agents disrupt intermolecular disulfide bonds, that are usually solvent exposed, and it is thought that 
the intramolecular disulfides remain unchanged. However, the structure of human Jagged1 (Figure I.3) 
enlightens that the intramolecular disulfides are, in these proteins, solvent exposed. Therefore, if 
protein refolding had failed or protein folded incorrectly, giving rise to an abnormal protein, there could 
be a completely random arrangement of disulfide bonds and possibly no secondary structure elements 
would be present in the resulting protein. In a DSF assay, we would expect total protein denaturation 
upon reducing agent exposition, with curves similar to those presented in Figure III.22-A and -B, high 
initial fluorescence that decays in function of temperature, indicative of protein:dye complexes 
precipitation at the starting point of the assay. On the contrary, if correct protein refolding had been 
successful, even if the pattern of disulfides is not C1-C3, C2-C4, C5-C6 (Knott, Downing et al. 1996), 
some structural elements would be present and a shift to lower Tm upon reduction is expected. 
In order to assess the influence of reducing agents in human Jagged2 DSL-EGF3 refolded from 
inclusion bodies, DSF was employed to monitor, if any, changes in protein Tm. The results from this 
assay are shown in Figure III.31. For both protein pools assayed, a thermal denaturation curve is 
observed even after incubation with reducing agents. However, we observe a shift to a lower Tm in the 
presence of both tested reducing agents (Figure III.31, purple and red curves) compared to the protein 
solutions without reducing agents (Figure III.31, blue curve). We therefore conclude that both protein 
samples present secondary structure elements and the predicted disulfide bonds. We cannot exclude 
however, the possibility of having a protein molten globule (Leal and Gomes 2007). 
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Figure III.31 - Influence of reducing agents in human refolded Jagged2 DSL-EGF3 protein 
pools assessed by DSF. Panel A - Pool 1 from SEC, Panel B - Pool 2 from SEC. Colour code of 
reducing agents is the same in both panels 
 
 
III.2.4.iii Analytical size exclusion chromatography 
To verify if the human Jagged2 DSL-EGF3 protein pools prepared after the SEC (as shown in 
Fig. III.27) were stable and homogenous, a protein aliquot of each protein pool was applied on an 
analytical SEC column. Analytical columns such as Superose 6 PC3.2/30 are designed to archive a 
highly resolving separation of biomolecules for the high theoretical plates combined with low flow 
rates. 
As one can observe in Fig. III.32, the elution volume of both protein samples is different, 
maintaining the relative differences observed in the initial preparative SEC (Fig. III.27), pool 1 having a 
higher elution volume than pool 2. This result confirms that each protein sample is stable and does not 
re-equilibrate to other species in solution. Moreover, it confirms that each protein sample contains one 
and only one species, i.e., that the separation of fractions to prepare each pool did not contribute for 
sample heterogeneity. 
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Figure III.32 - Analytical Size Exclusion Chromatograms for human Jagged2 DSL-EGF3 
purified from inclusion bodies. Injection is marked in pink and volume was corrected to zero at 
that point. Protein was monitored by absorbance at 280nm and recorded (left vertical axis) in red for 
Pool1 and in blue for Pool2. Each Protein sample was run independently and the chromatograms 
superposed in UNICORN software. 
 
 
We conclude that these constructs are not amenable for bacterial expression nor for soluble 
protein purification, as only around 20% soluble protein, as estimated by Western Blot analysis, could 
be obtained, and the target proteins could not be purified from the bacterial contaminants after tag 
cleavage. We conclude also that, even when purifying human Jagged2 DSL-EGF3 refolded from 
inclusion bodies with high yields, as reported previously for a similar construct of hJag1 (Cordle, 
Johnson et al. 2008), we could not obtain a homogenous sample in terms of disulfide pattern, which 
can compromise significantly the crystallization attempts (Section III.5). 
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III.3. Mammalian Expression System 
 
In order to assess the expression of each protein construct in mammalian cell expression system, 
the Notch ligands domains previously cloned in pET47b were also successfully cloned in pHL-SEC 
vector (Aricescu, Lu et al. 2006). As part of the European project P-CUBE, the constructs were sent to 
OPPF and the small scale expression screenings performed as follows. 
 
III.3.1 Small-scale expression screenings and Protein purification at 
OPPF 
All plasmids were transiently transfected in adherent HEK293T cells encoding each protein, 
preceded with a secretion signal, and with a C-terminal His-tag. Supernatant samples harvested 48h 
post-transfection were analysed by WB using an anti His-tag antibody (Figure III.33). Three constructs 
did not show expression of the respective proteins (hJag1 MNNL-EGF3, hJag2 MNNL-EGF9 and 
hJag2 DSL-EGF9). This may be due to a premature stop before the translation of the C-terminal His-
tag. The former construct sequencing result confirmed that the DNA sequence was as expected but 
the later constructs’ result failed to confirm the presence of the correct sequence at the 3’ end. This 
can explain that the lack of result for hJag2 MNNL-EGF9 and hJag2 DSL-EGF9 protein expression 
might be due to a DNA level error. All the other tested constructs gave a positive result with intense 
bands corresponding to the expected size of each protein except for hJag1 MNNL-EGF9 with one 
higher and hDll1 DSL-EGF3 with one lower molecular weight contaminant protein. 
 
Figure III.33 – Western Blot analysis of small scale expression screenings in adherent 
HEK293T cells with anti His-tag antibody. Exposure time: 10 seconds. M – MNNL domain; E – 
EGF domain; D – DSL domain. 
 
The construct encoding hDll1 DSL-EGF6 showed the more intense band of all the tested 
constructs. As such, a large-scale protein production and purification was pursued using the standard 
conditions used in OPPF. 
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III.3.2 Purification of human Delta-like Ligand1 DSL-EGF6 at OPPF 
Six litres of media were harvested from 24 expanded surface roller bottles, clarified, diafiltered 
and applied into cobalt beads for metal affinity purification. Eluted protein was concentrated and two 
injections were performed in a S200 SEC column. The resulting chromatogram is shown in Figure 
III.34.  
 
Figure III.34 – Size exclusion chromatogram for the purification of human Dll1 DSL-EGF6. 
Injections are marked in pink. Protein was monitored by absorbance at 280nm and recorded (in 
blue, left vertical axis). The eluted fractions are shown in red in the bottom and those analysed in 
the SDS-PAGE in Figure III.35 in black. 
 
Both injections showed the same profile, with four peaks having the same elution volume. The 
first peak was more intense in the second injection, which may indicate protein aggregation with time. 
The peaks resulting from the first infection were analysed by SDS-PAGE in as well as the previous 
step’s samples (Figure III.35). 
The samples from the batch metal affinity purification reveal that some protein was lost during the 
washing steps, but the amount was negligible when comparing with the amount of contaminants 
removed from the chromatography media (Figure III.35). Nevertheless, some degree of protein 
contamination was present, in the sample injected in the SEC column. Regarding the samples from 
the SEC column (Figure III.34), as expected, the first three peaks correspond to higher molecular 
weight contaminant proteins as one can observe in the lanes corresponding to Fractions 1C1, 1C7 
and 1C11. The fourth and most intense peak corresponds to human Dll1 DSL-EGF6 with a molecular 
weight of around 32kDa, as in Table III.2. 
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Figure III.35 – SDS-PAGE analysis of human Delta-like1 DSL-EGF6 purification. Purification 
using cobalt beads (in batch) and SEC fractions were analysed.  
 
The fractions corresponding to each peak were pooled and concentrated separately. The first 
peak was pooled and readily concentrated as the second injection was still running. As some 
precipitation occurred during the first chromatogram peak concentration, 300mM NaCl was added to 
pool 1 in order to stabilize the protein due to the increase in ionic strength. As this did not appear to 
solve the precipitation issues, we further added 5% glycerol as a stabilizer. As such, pool1 buffer 
composition is 10mM Hepes, 300mM NaCl, 5% Glycerol, pH 7.5; the protein pool1 was concentrated 
to 4.7mg/mL and resulted in 2.35mg of protein. 
With the previous knowledge taken from Pool 1 concentration, and envisioning the crystallization 
trials (Section III.5 - Protein Crystallisation ), we added 650mM NaCl, omitting glycerol addition, prior 
to the concentration steps and this prevented precipitation events. Pool2 was concentrated to 
4.6mg/mL, 1.27mg of protein in 10mM Hepes, 650mM NaCl, pH 7.5. Both protein pools were used to 
set up crystallization trials at OPPF/HTX and the remaining protein samples were shipped to IBET. 
 
III.3.3 Biophysical characterisation of human Dll1 DSL-EGF6 at IBET 
To evaluate the purified Dll1 DSL-EGF6 protein expressed in mammalian cells, DSF assays were 
employed. EGF4 and EGF7 are two putative calcium binding EGFs present in hDll1 protein as 
predicted by UniProtKB (http://www.uniprot.org, accession O00548). As such, it would be expected 
that the produced protein, encompassing EGF4, could be influenced by the presence or absence of 
calcium ions. As the protein could have calcium ions bound or they could have been lost during the 
purification, each protein pool was assayed using the respective buffer and with equimolar EDTA, a 
chelating agent, or two molar fold CaCl2 incubation. 
The Dll1 thermal denaturation curves (Figure III.36-A, solid blue and green lines) exhibit high 
initial fluorescence (HIF), and low intensity denaturation curves with essentially the same melting 
temperatures, 65-66°C. This may suggest that part of the purified protein may be in an unfolded but 
soluble state, and only a small portion is able to denaturate i.e. folded. This result suggests that the 
chosen purification buffers are not optimal for this protein, and a buffer screen could elucidate a better 
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option for the next purification. The HIF could also be protein dependent in the case that this protein 
has more exposed hydrophobic areas. 
 
 
Figure III.36 – DSF assays for human Dll1 DSL-EGF6 produced in mammalian cells and 
purified at OPPF. Panel A – Representative denaturation curves for each protein pool and the 
results obtained upon incubation with equimolar EDTA or two molar fold CaCl2; Panel B – First 
derivative of the data presented in Panel A. Curves for Pool1 in blue and for Pool2 in green. 
 
Regarding the assays with CaCl2 and EDTA, both protein pools appear to behave in a similar 
manner: calcium incubation causing a slight decrease in the denaturation curves intensity, and EDTA 
increasing it. Our results regarding the influence of EDTA in protein stability do not show significant 
differences in protein Tm (-1°C), possibly indicating that the protein does not have calcium ions bound, 
although addition of CaCl2 to the DSF assay does show an improvement of 1°C in protein stability. 
This can possibly indicate that either the incubation time was not sufficient for calcium ion 
incorporation or that the putative calcium sites are not actually present. 
From the DSF analysis of the first derivative (Figure III.36-B), pool 2 shows sharper curves than 
pool 1, maybe indicating that the transition between the native and unfolded protein species is more 
cooperative. Comparing the sharpness of the first derivative between pool 1 and pool 2 we can 
conclude that hDll1 DSL-EGF6 is more stable in high salt concentrations. This result in the DSF assay 
may also indicate that pool 2 sample can be more prone to crystallize, due to its higher homogeneity 
(Santos, Bandeiras et al. 2012). 
In order to screen for a buffer formulation in which human Dll1 DSL-EGF6 is more stable, a DSF 
buffer screen was performed (Figure III.37). Two sets of denaturation curves were chosen based on 
the denaturation profile, showing one (panel A) or two melting transitions (panel B). 
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Figure III.37 - DSF buffer screen for human Delta-Like Ligand1 DSL-EGF6. Panel A – Non-
normalized denaturation curves with one transition compared to the Reference; Panel B – Non-
normalized two-transition denaturation curves; Panel C - Normalized denaturation curves of the 
selected condition presented in Panels A and B. Colour code for each Buffer system is the same 
across panels. 
 
Overall, the thermal denaturation curves with a single melting transition show lower Tms. Despite 
the lower Tm, those buffers present a single cooperative protein denaturation profile which may 
suggest the presence of a more homogenous sample (Santos, Bandeiras et al. 2012). All buffers 
showing two melting transitions display a higher Tm than the reference sample. Based on the fact that 
Na/K phosphate pH 6.0, 500mM NaCl with 63°C and ADA pH 6.5, 500mM NaCl with 68°C display the 
lowest initial fluorescence, sharpest melting transition and highest Tm, we believe these two buffers 
formulations can be good options. 
For protein crystallization purposes the best buffer option is one that provides an homogeneous 
sample and as such, Sodium / Potassium phosphate pH 6.0, 500mM NaCl is chosen for the next 
purification batch of hDll1 DSL-EGF6. 
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III.4. Mammalian expression at iBET 
III.4.1 Expression of Notch ligands constructs in pHL-sec vector 
In order to reproduce the small scale expression results obtained at OPPF, to validate the 
expression protocol at our lab and to generate more hDelta-Like Ligand1 DSL-EGF6 protein, all four 
human Delta-Like Ligand1 constructs were transfected into HEK293T adherent cells and conditioned 
media harvested to western blot analysis (Figure III.38). 
 
Figure III.38 - Western Blot analysis of hDll1 constructs in pHL-sec transfected into HEK293T 
adherent cells. The protein domains and time of media harvest (in hours) are depicted above 
(panel A) or below (panel B) the corresponding lanes. A - Initial result obtained with the protocol 
from OPPF (see Figure III.33); B - Result obtained after loading ten times the sample volume. 
Previously purified proteins were also loaded as controls. Faint bands are highlighted by the red 
squares. 
 
Our results showed great differences regarding the expression profiles when compared to those 
obtained at OPPF using the same plasmid constructs and the same cells as expression host. 
Moreover we detected the presence of an unspecific band, assigned to be a contribution from the 
serum proteins. Nevertheless, we could obtain a positive signal for the presence of hDll1 DE3 protein 
(Figure III.38-A) and, in order to better evaluate the expression profiles of the remaining constructs, a 
new western blot analysis was performed. This assay was pursued with a ten-fold increase in the 
amount of each sample, and the membrane was clipped below the 63kDa protein in the molecular 
weight marker to prevent the unspecific band to react with the antibodies (as in panel A). Also, for size 
comparison and a rough estimate of the amount of protein, proteins purified previously were also 
loaded in the gels, as indicated. We could observe faint bands indicating low amounts of hDll1 ME3 
and DE6 proteins with this new analysis (Figure III.38-B). Comparing the results obtained using OPPF 
protocol to those obtained at OPPF (Figure III.33) we could not obtain similar expression results. As 
such, the expression profiles of these constructs were also assessed in suspension adapted HEK293T 
cells (Figure III.39). 
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Figure III.39 – Western blot analysis of human Dll1 constructs' expression upon DNA 
transfection into suspension adapted HEK293T cells. Exposure time is 120 seconds. The 
expected molecular weight for each protein is marked with red arrows. 
 
Human Dll1 DSL-EGF3 was, once again, the only construct for which protein expression was 
detected in the Western Blot analysis. As hJag2 DE3 protein was used as both an antibody control 
and a quantification estimative, we could observe that the expression levels were still very low. 
Moreover, the proteins' apparent molecular weight seems to be slightly higher than expected, as 
indicated by the arrows across figures hereafter. The results obtained thus far did not reveal to be 
promising using HEK293T cells. 
HEK293T and HEK293-EBNA cells were engineered to express SV40 large-T antigen or Epstein-
Barr virus (EBV) nuclear antigen-1 protein, allowing the episomal replication of plasmid DNA with 
SV40 or EBV origin of replication sequences, respectively ((Pear, Nolan et al. 1993) and Invitrogen's 
manual Catalog no. R620-07, Version C/102810/25-0347 available online at http://tools.lifetech-
nologies.com/content/sfs/manuals/293ebna_man.pdf as for September 2014). Taking this knowledge 
in consideration, we pursued expression trials with HEK293-EBNA cells (Figure III.40) in order to 
increase protein production yields as reported for Antibodies and Ab-fusion proteins (Jager, Bussow et 
al. 2013). As far as we know pHL-sec plasmid originated from a series of modifications of pCAβ-EGFP 
plasmid, where SV40 origin was removed (Yaneza, Gilthorpe et al. 2002). pHL-sec thus can possibly 
be maintained in both HEK293 cell types. We therefore sought to investigate whether in HEK293-
EBNA cells the expression of our constructs would lead to secretion of correct molecular weight 
proteins. 
The human Dll1 constructs in the pHL-sec vector backbone were transfected in suspension 
adapted HEK293-EBNA cells as in Section II.5.2.iii. The result was evaluated by Western Blot (Figure 
III.40). 
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Figure III.40 – Western blot analysis of human Dll1 constructs' expression upon DNA 
transfection into suspension adapted HEK293-EBNA cells. Exposure time is 300 seconds. The 
expected molecular weight for each protein is marked with red arrows. 
 
The hDll1 DE3 protein shows the highest expression, consistent with all the previous western blot 
analysis. The construct encompassing DSL to EGF6 domains (D-E6), that gave the best results in the 
OPPF small scale screenings (see Figure III.33), generated only modest protein expression when 
compared to the former construct.  
Aiming to increase cell viability and expression rate, a second small scale expression trial was 
performed as before with an additional step of 1% FBS feeding 24 hours post transfection (Figure 
III.41). This strategy was followed since serum feeding post-transfection has been shown to improve 
cell viability, contributing for higher viable cell densities and consequently higher productivities (Pham, 
Perret et al. 2005). 
 
 
Figure III.41 – Western blot analysis of human Dll1 constructs' expression upon DNA 
transfection into suspension adapted HEK293-Ebna cells feeded with 1% FBS at 24hpt. Exposure 
time is 300 seconds. The expected molecular weight for each protein is marked with red arrows. 
 
The results obtained with post transfection feeding were still not substantial, with hDll1 DE3 
construct having the only detectable expression. Once again, the apparent molecular weight of each 
protein ranged far from expected. It is possible that the signal peptide encoded by the vector is not 
fully processed in the HEK293-EBNA cells, as it seems to be in HEK293T cells used at OPPF, 
causing the molecular weight shift. It is also possible that the unprocessed signal peptide is precluding 
the correct export across the plasma membrane, reducing the levels of detectable protein in culture 
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supernatants. Surprisingly as well, the protein expressions obtained are not comparable to those 
obtained without serum feeding (Figure III.40). This can perhaps be due to the unspecific antibody 
binding to FBS in the Western Blot procedure, precluding the detection to the heterologous expressed 
proteins in lower levels. Also, the images acquired with higher exposure time (not presented) do not 
show protein expression different than the presented figure, possibly due to limitations of the detection 
device. 
 
Striving to generate more protein using mammalian cells as expression host, we pursued the use 
of a different vector backbone for transfection. 
 
III.4.2 Expression of Notch ligands constructs in pTT22SSP4 vector 
 
The cDNAs encoding human Jagged1 ME9, Jagged2 ME9 and Dll1 ME6 and DE6 domains were 
cloned in pTT22SSP4 vector, which has been successfully used for TGE in HEK293-EBNA cells 
(Durocher, Perret et al. 2002). We followed with these protein domain constructs as they correspond 
to the largest fragments of each protein in this study plus the construct that was already purified at 
OPPF. 
The expression profiles were assessed in HEK293-EBNA suspension adapted cells transfected 
with each plasmid in both secreted and intracellular forms (Figure III.42). 
Each of the tested proteins shows an intense intracellular expression (Figure III.42, right half). All 
of the tested pTT22SSP4 constructs give rise to proteins with molecular weights similar to the 
predicted ones (Table III.2). 
 
 
Figure III.42 - Western blot analysis of Notch ligand constructs in pTT22SSP4. Normalised 
amounts of condition media and cell lysate were evaluated for expression with anti-His antibody. 
Exposition time: 300 seconds. 
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We found that hDll1 DSL-EGF6, the protein produced at OPPF, gives rise to the best result 
obtained in secreted form in this particular experiment, being the only slightly detected protein in 
secreted form, as indicated by the orange arrow (Figure III.42, left half). Since some assessments and 
characterisation were already performed in hDll1 DE6 protein from OPPF, it would be of interest to 
generate higher amounts of this protein that could be purifiable at our lab. 
 
Several additives are being studied to improve recombinant protein production yields in 
mammalian cells such as DNA methyl transferase (iDNMTs) and histone deacetylase (iHDACs) 
inhibitors and protein hydrolysates. The former act by inhibiting plasmid DNA methylation or 
association with deacetylated histones, increasing the plasmid's half-life in the transfected cells' 
nucleus, promoting transcription of extra-chromosomal DNA prior to physical loss of the plasmid 
(Backliwal, Hildinger et al. 2008). On the other hand protein hydrolysates, or peptones, counteract the 
nutrient depletion in the high density cultures, may improve gene expression through regulation of 
transcriptional and translational machinery and provide an additional source of aminoacids after 
transfection (Pham, Perret et al. 2005). 
We carried out a small scale expression screening for the construct encompassing hDelta-Like 
Ligand1 DSL-EGF6 domains using different feeding strategies. The cultures were transfected and, 24 
hours later, fed with Valproic Acid (VPA) and Pancreatic digest of Casein (Tryptone) as these 
additives showed the best results in those studies mentioned above (Figure III.43). 
 
 
Figure III.43 - Western blot analysis of hDll1 DE6 expression after feeding with reported 
enhancers of protein expression in mammalian cells. Both 0.5 (top) and 1mg (bottom panel) of 
DNA per culture litre were tested for protein expression in the absence and presence of VPA and/or 
Tryptone feeding post transfection. Exposition time: 300 seconds. 
 
As expected, the non-transfected control showed no band and the transfected cultures showed 
increasing amounts of hDll1 DE6 with time for both DNA concentrations tested. The use of 1mg of 
DNA per liter condition (Figure III.43, bottom panel) rendered a higher protein expression than 
0.5mg/L (top panel). Regarding our results with both feeding additives for protein expression 
enhancement, we saw no increase in protein expression compared to the transfected only cultures, 
rather a decrease of it. Feeding with Tryptone proved more efficacious than VPA either in cultures 
transfected with 0.5 or 1mg/L, although the levels of secreted recombinant protein did not supplant 
those obtained without feeding additives.  
It may be that the concentration-dependent VPA action in stabilizing transgene's mRNA levels is 
not followed by a stable increase in transcriptional activity as reported by Wulhfard (2009). In 
concentrations of 3.75mM VPA and above, cells' viability is severely compromised within seven days 
post-transfection (Wulhfard 2009), although this concentration was reported as having the highest 
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positive effect in expression enhancement (Backliwal, Hildinger et al. 2008). Moreover, hystone 
deacetylase inhibitors have been shown to decrease cell viability and to have a profound anti growth 
activity in vivo (Cinatl, Cinatl et al. 1997, Takai, Desmond et al. 2004). For its ability to modulate 
expression profile of transgenes, one can hypothesise that VPA modulation is not restricted to 
exogenous transcripts but may also interfere with the cells' physiological pathways. In fact, Greenblatt, 
Vaccaro et al. (2007) reported that VPA activates Notch-1 signalling, increasing its expression at the 
cells' surface. Therefore, it is possible to conceive that if the pathway is activated by VPA in the 
expressing cells, more interactions between the endogenous over-expressed receptor and our 
heterologously expressed ligand (that contains the minimal Notch binding domain) could occur, 
sequestering the recombinant protein and diminishing its availability. 
Pham, Perret et al. (2005) reported a series of peptone feedings in HEK293E cells and found that 
some (namely CPN3, C1, GPN2 and GPN3) had little or negative effects in augmenting recombinant 
SEAP protein expression. Regarding the results obtained with Tryptone, our results can possibly 
reflect one of such cases, in the event of a system dependence of peptone feedings. We did not carry 
a comprehensive analysis of several peptones and only pursued with the protein hydrolysate reported 
as a better enhancer. Perhaps the effects of protein hydrolysate feedings can be system-dependent 
and what is true for a particular system may not be of suitable use for another. 
 
For this particular construct of human Dll1 DSL-EGF6 in pTT vector, we therefore determined that 
a medium scale production of 1.5L culture, performed with 1mg/L DNA tranfection with PEI, harvested 
at 118 to 126hpt would be performed. The purification scheme was as HisTrap column affinity 
purification (Figure III.44) followed by SEC (Figure III.46). 
 
 
Figure III.44 - Elution chromatogram of HisTrap affinity purification of hDll1 DE6 (in 
pTT22SSP4) from HEK293-Ebna cells' conditioned media. Bound protein was eluted with steps 
of increasing concentrations of imidazole (buffer B, right axis) monitored by absorbance at 280nm 
(in blue, left axis. The analysed fractions (Figure III.45) are shown in black. 
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After conditioned media injection and column wash, bound protein was eluted in steps of 
imidazole. In each step, a single peak was eluted (Figure III.44). Selected fractions were analysed by 
SDS-PAGE in order to discern in which peak hDll1 DE6 was eluted (Figure III.45). 
 
Figure III.45 - SDS-PAGE analysis of hDll1 DE6 HisTrap affinity purification fractions from 
Figure III.44. Highlighted in orange are the fractions containing hDll1 DE6 protein (32kDa). 
 
By analysing the SDS-PAGE in Figure III.45, we can observe the presence of an intense band in 
the samples from the eluted fractions 21 trough 41, highlighted in orange. Those samples match to the 
second and third peaks of the elution chromatogram (Figure III.44), corresponding to an elution with 
imidazole concentrations of 100 and 150mM respectively. 
In order to confirm the identity of the eluted protein, a MS/peptide fingerprinting was performed 
and the protein identity shown the protein to be in fact human Delta-Like Ligand1 DSL to EGF6 
domains (Section VI.4). 
The fractions containing hDll1 DE6 were pooled and injected in a S75 SEC column in order to 
separate our protein of interest from the remaining contaminants (Figure III.46). 
 
Figure III.46 - Size exclusion chromatogram of hDll1 DE6 purification. Injection is marked in 
pink. Protein was monitored by absorbance at 280nm (in blue, left axis). Fraction numeration is 
shown in the bottom, being those analysed in Figure III.47 in black. 
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Selected fractions from the eluted protein were analysed by SDS-PAGE (Figure III.47, in black). 
As one can observe in the gel analysis, the first peak corresponds to high molecular weight 
contaminants and the second to our target, human Dll1 DSL-EGF6, with high purity. 
 
 
Figure III.47 - SDS-PAGE analysis of hDll1 DE6 SEC fractions. Highlighted in orange are the 
fractions containing the protein of interest (32kDa). 
 
The fractions from the second peak were pooled and concentrated to a final volume of 230µL and 
protein concentration, as determined by Bradford assay, to be 0.9mg/mL, 207µg total. 
 
Here, we finally found that with this TGE system using HEK293-EBNA cells and pTT vector-
based constructs we can express our proteins of interest that can be purified with a two-column 
purification scheme. Although the technical difficulties are higher than in bacterial systems, we could 
obtain a pure protein sample. 
The protein obtained was used for a study of another Master student Thesis, Maria Jardim 
Cabral. The aim of Maria’s work is to select specific Fab’s against a target protein that intervenes in 
the Notch1 signalling pathway – the DLL1 ligand, using the phage display technology. As such a 
panning campaign was carried out using the purified protein. 
 
III.5. Protein Crystallisation  
III.5.1 hJagged2 DSL-EGF3 protein purified from inclusion bodies 
Protein crystallisation experiments were performed before all the characterizations of hJag2 DE3 
described above were completed. As such, both protein pools were used in a grid screen around the 
published crystallization condition of hJagged1 DSL-EGF3 (Cordle, Johnson et al. 2008): sitting drops 
by the vapour diffusion technique at 4.6mg/ml, 0.2μl of protein and 0.2μl of mother liquor in 8.5% (w/v) 
PEG 4000, 100mM Imidazole/Malate, pH 7.0. Precipitant was varied between 7.5 and 11% PEG 4000 
in 100mM and 200mM Imidazole/Malate, pH 7.0. 
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Neither condition tested produced a positive result nor something useful for a follow up 
experiment. 
 
Consequently, crystallisation space was sampled with the commercially available screens as 
depicted in Table III.5. 
 
Table III.5 – Nano-scale crystallisation commercial screens performed with human Jagged2 
DSL-EGF3 purified from Inclusion bodies. 
Crystallisation 
Screen 
Temperature 
(°C) 
Protein 
Pool 
Protein conc. 
(mg/mL) 
Stura FootPrint 20 1 5,5 
Structure 1+2 20 
1 5,5 
1 7,5 
2 7,9 
Index 20 
1 7,5 
2 7,9 
PactPremier 20 
1 7,5 
2 7,9 
SaltRx 
20 
1 7,5 
2 7,9 
4 
1 7,5 
2 7,9 
MPD 
20 
1 7,5 
2 7,9 
4 
1 7,5 
2 7,9 
Cryos 
20 
1 7,5 
2 7,9 
4 
1 7,5 
2 7,9 
 
The screens were performed in chronological order as presented in Table III.6. The Stura 
Footprint together with Structure 1+2 screens were used for an initial assessment of the protein 
precipitant solubility curve and for sampling the crystallization space with a classical sparse matrix 
screen, respectively. hJag2 DSL-EGF3 protein at 5.5mg/mL was used for this initial assessment since 
the hJag1 DE3 protein was crystallised at a similar concentration (Cordle, Johnson et al. 2008). 
After visual inspection of the crystallization screens, we could observe that more than 90% of the 
drops were clear, with no signs of precipitation. This indicates that most of the tested conditions are 
below the saturation curve of the phase diagram (Fig. III.48). Given that Footprint screen explores the 
protein solubility curve, we could conclude that the protein samples needed to be further concentrated 
in order to drive the system towards saturation. 
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Figure III.48 - Schematic illustration of a protein crystallization phase diagram. The adjustable 
parameter can be precipitant or additive concentration, pH, temperature and so on. The solubility is 
defined as the concentration of protein in the solute that is in equilibrium with crystals. Figure from 
Khurshid, Saridakis et al. (2014) 
 
After a second round of protein concentration, both protein pools after hJag2 DE3 refolding 
(Section III.2.4.ii) were assayed with Structure 1+2 screen. The visual inspection over the first days 
revealed that the newly obtained protein solutions were more prone to be in the concentration range 
appropriated for crystallization. A more even distribution of clear and precipitated drops was obtained. 
Therefore, the remaining screens presented in Table III.6 were performed. Amongst the available 
screens in our group, these were selected based on the variety of different reagents' combinations, 
widely sampling crystallization space. Index is a data-driven biased sparse matrix and grid seen. This 
screen followed the initial experiments for its broad range in crystallization space sampling and for its 
data-driven construction, i.e., a combination of crystallization solution that were reported to produce 
crystals in the literature. PactPremier screen is a systematic grid screen that could provide invaluable 
clues on the protein behaviour in the crystallization plate. On the other hand, SaltRX screen is a pH 
and salt matrix screen, sampling a variety of different salts as precipitating agents in a wide pH range, 
two of the factor that are reported to be crucial for macromolecular crystallisation (McPherson 1990). 
Ultimately, MPD and Cryos screens were performed. Both screens have the advantage of 
including cryoprotectant agents in all solutions. MPD is, as Index, a data-driven grid screen. MPD (2-
methyl-2,4-pentandiol) is a precipitant and a cryoprotectant. The rationale for the use of this screen is 
that MPD lowers the chemical activity of water, thereby reducing the electrostatic interactions between 
the solvent molecules and the protein in solution, promoting crystallization. Cryos is a sparse matrix 
screen and has glycerol as a cryoprotectant.  
 
In spite of the amount of crystallization conditions tested and the vast sampling of the 
crystallization space, no positive results were obtained. All the drops were either clear or precipitated 
after plate set up. Few clear drops evolved, and those that evolved were to a slight precipitate. Some 
drops provided crystals that were unbreakable by touch, meaning that those were salt crystals. 
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The fact that none of the protein samples assayed in the crystallization experiments was 
homogeneous in terms of dissulfide pattern (Fig. III.30) may contribute to the lack of success in this 
stage. It is absolutely crucial to have a pure and homogeneous sample for crystallization (McPherson 
1990), having the later not been accomplished. 
 
III.5.2 hDelta-Like Ligand1 DSL-EGF6 purified from mammalian cell 
culture at OPPF 
 
Straight after the last protein purification step of hDll1 DE6, all the screens listed in Table III.7 
were performed. This list encompasses the most utilised screens at OPPF, those that generally 
produce crystals of the variety of proteins produced and purified by the applicants of the European 
project P-CUBE. 
 
Table III.6 - Nano-scale crystallisation commercial screens performed with human Delta-Like 
Ligand1 DSL-EGF6 purified from mammalian cells at OPPF. 
Crystallisation 
Screen 
Temperature 
(°C) 
Protein 
Pool 
Protein 
Concentration 
Hampton Crystal 
Screen 1&2 
20 
1 4.7 
2 4.6 
PEG/Ion Screen, 
Grid Screen P6K, 
Grid AmSO4 
20 
1 4.7 
2 4.6 
Salt Rx 20 
1 4.7 
2 4.6 
Index 
20 
1 4.7 
2 4.6 
4 
1 4.7 
2 4.6 
Morpheus 20 
1 4.7 
2 4.6 
Pact Premier 20 
1 4.7 
2 4.6 
 
Crystallization experiments at OPPF were remotely monitored through xtalPIMS, which is part of 
the Protein Information Management System (PIMS) which covers crystallization. Drops were 
monitored by the automated hotels with integrated imaging system both at 4 and 20°C. All drops were 
imaged with the defined OPPF schedule: immediately after setup, 4-5 hours later, every day for one 
week, weekly for a month, and monthly thereafter until the cessation of the experiment. At each 
inspection, an automated e-mail was received with the link for the new set of images. 
All images acquired by the automated system were readily visualised and no positive result was 
obtained after 222 days (which is the limit of the experiment in the OPPF-HTX facility) in any of the 
1344 tested crystallisation conditions. However, one crystal was obtained (Figure III.49) but it was 
not possible to clarify on the salt or protein nature of such crystal. 
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Figure III.49 - Crystal obtained at OPPF-HTX facility. A - Automated image of the drop 
(crystallisation condition: 20% (w/v) Polyethylene Glycol 3350, 0.2M Sodium Fluoride). B - Manually 
acquired image of the crystal shown in A with a polarised filter. 
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Chapter IV Conclusions and Future Perspectives 
 
With the work presented in this thesis, we opened new views for the expression and purification 
of Notch ligand extracellular domain. 
Although bacterial expression systems are widely the first choice host organisms for protein 
production, we can conclude that because of the nature of our target proteins they may not be 
suitable. These ECD portions of Notch ligands are hard targets to express and purify, due to their 
pencil-like shape conformation and disulfide bond content that overwhelm the bacterial cell machinery. 
As for the purification yields, we could obtain a large amount of hJag2 DSL-EGF3 refolded protein 
(26.8mg per culture litre) although the quality of the final product could not be ascertain as excellent. 
With the mammalian expression system we obtained a much lower amount of hDll1 DSL-EGF6, and 
this was due to the low expression yield (603µg/L at OPPF, and 138µg/L at iBET). Nevertheless, to 
accomplish the main goal of this project – function-blocking antibodies that can exert their effect in 
vivo – quality is more important than quantity in our opinion. 
As such, we can now begin to understand how the Notch ligand domains behave as 
recombinantly expressed proteins in the test tube. With the knowledge here generated, a more 
informed choice of expression organism, vector system, and expression conditions may be followed in 
order to obtain pure and homogeneous protein samples for the extracellular domain portions of Notch 
ligands. 
 
In face of the knowledge brought by the presented work, we aim to continue the efforts in 
expressing and purifying Notch Ligand protein domains. The work developed in this thesis did not 
totally answer all the questions that were raised throughout the entire experimental work. However, 
this thorough study lead us to a broader knowledge on the behaviour of these types of proteins, and 
this know-how will be critical for the next steps this project.  
We must express and purify more hDll1 DE6 protein, since this is essential to extend the 
crystallization experiments using higher protein concentration and different crystallization screens. 
Once the expression in HEK293 cells and protein purification protocols are optimized, and we obtain 
more protein sample, the continuation of the crystallisation experiments will be pursued. Since the 
panning campaign has started using human Dll1 DSL-EGF6 protein purified herein, we are a step 
closer to obtain antibody fragment candidates to pursue for protein expression and purification. 
The hDll1 DSL-EGF6 protein will also be used to characterise the binding affinities of the selected 
antibody fragments after their purification. We also aim to co-crystallise the antibody:protein complex 
with the most promising antibody fragments, those that show a higher binding affinity for example. We 
hope that the latter serves as well as a crystallisation scaffold. With the knowledge that will be 
obtained from the protein structural model, alone and in complex with its Fab counterpart, we hope to 
be contributing to the elucidation of the molecular features that a function blocking antibody for Notch 
ligands may require, and understand why and how the Notch1 inhibition pathways functions via 
blockage of the Dll1 association. 
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In case the attempts with mammalian expression fail for the remaining constructs, we can always 
try to increase the percentage of soluble protein obtained with bacterial expression systems. We 
believe that, even though the quantities are low, an upscale of the whole upstream process would 
allow a fair amount of protein to be recovered and used for further studies. In such a case, we would 
however recommend no tag cleavage attempts to be performed so that we would always have an 
easy method to detect our target protein by Western blot, using an anti-tag antibody. Also, more 
efforts can be put together in exploring other expression conditions in SHuffle
®
 strain than those 
presented. Other E. coli modified strains for cytoplasmic disulfide formation such as Origami and 
derivatives could also be tested attempting to screen for the strain with the modification(s) most 
suitable for the correct expression of our target protein domains. Yet other option could be the 
periplasmic expression of our target proteins using different vector backbones, for example pET39b or 
pET40b that harbour the coding sequence of disulfide oxidoreductase DsbA and disulfide isomerase 
DsbC respectively. 
 
With the generation of different protein samples, we hope to generate more antibody fragments 
and characterize their binding affinities carrying out assays using SPR, Biacore or Octet. The selected 
antibody fragments will be ranked according to binding affinities and kinetics. The top ranked 
fragments that show the highest binding affinity will be subsequently used in the crystallisation 
experiments, cellular assays and elucidation of the molecular features of the function blocking 
antibodies.  
We hope that we can select a couple of good lead candidates that will be further tested in cellular 
assays, for Notch pathway inhibition. For example, cell proliferation assays will be conducted to 
determine the effect of the isolated anti-Dll1 on the growth of breast cancer cells with moderate or high 
level expression of Dll1. 
 
With the increased knowledge generated by the work presented in this thesis and the future work 
ahead, our goal is to find a highly specific and active function blocking antibody for Notch ligands, and 
this will help elucidating the molecular basis of anti-Dll1 antagonistic activity in the Notch1 signaling 
pathway. 
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Chapter VI Appendix 
VI.1. Reagents List 
Table VI.1 - Reagents and equipments used in this study, organized by alphabetical order. 
Reagent / Equipment Supplier Catalogue number 
24-well Cryschem Plate Hampton Research HR3-158 
2xYT media Applichem A0981 
3L Fernbach design erlenmeyer Corning 431252 
96-well low profile plates  Bio-Rad MLL9651 
Agar Nzytech MB02902 
Agarose SeaKem 50004 
AgeI  NEB R3552S 
Amicon 10kDa MWCO Millipore UFC901024 
Amicon Stirred Cell unit  Millipore 8050 
Ampicillin Sigma A9518 
BamHI Fermentas ER0055 
BenchMark™ Protein Ladder Invitrogen 10747-012 
Benzonase Novagen 70746 
Beta-mercaptoethanol Carl Roth GmbH 4227.1 
Bio-Rad Protein Assay Dye Reagent 
Concentrate 
Bio-Rad 500-0006 
BugBuster Protein Extraction Reagent Novagen 70584 
Calcium chloride Calbiochem 3000 
Chloramphenicol Sigma C0378 
Criterion XT Precast Gel Bio-Rad 
345-0124 / 
345-0125 
CrystalQuick™ 96 Well, Greiner Hampton Research HR3-281 
Cystamine Sigma 30050 
Cysteamine Sigma M6500 
DMEM Gibco 41966 
DMEM Sigma D6546 
dNTP mix Nzytech MB08604 
EcoRI Fermentas ER0271 
EcoRV  Fermentas ER0305 
EDTA Carl Roth GmbH 8040.2 
FCS 
Gibco 16250 
Invitrogen 10270 
FreeStyle 293 media Gibco 12338 
FreeStyle F17 media Gibco A13835 
GeneJET Plasmid Miniprep Kit Fermentas K0502 
Gentamycin Gibco 15710 
Glutamax Gibco 35050 
Glycerol Calbiochem 4760 
Goat α-mouse IgG-HRP conjugated 
antibody 
Sigma A9917 
GSH Sigma G4251 
GSSG Sigma G4376 
GSTrap column GE Healthcare Life Sciences 17-5281-01 
ii 
 
Reagent / Equipment Supplier Catalogue number 
Hepes Carl Roth GmbH 9105.3 
HiLoad 16/600 Superdex 200 pg 
column 
GE Healthcare Life Sciences 28-9893-35 
HiLoad 16/600 Superdex 75pg column  GE Healthcare Life Sciences 28-9893-33 
HindIII Fermentas ER0501 
HiPrep 26/10 desalting column GE Healthcare Life Sciences 17-5087-01 
HisTrap column  GE Healthcare Life Sciences 17-5248-02 
Imidazole Merck 1.04716.1000 
IPTG Nzytech MB02602 
Kanamycin Sigma K1876 
Kifunensine Cayman Chemical 10009437 
Klenow fragment Fermentas EP0051 
KpnI  Fermentas ER0521 
L-arabinose  Sigma A3256 
L-Arginine Sigma W381918 
Lipofectamine2000 Invitrogen 11668-019 
MES Running Buffer Bio-Rad 161-0789 
Milk Powder Molico n/a 
Mini-PROTEAN TGX precast Gels Bio-Rad 
456-1083 / 
456-1086 
MOPS Running Buffer Bio-Rad 161-0788 
Mouse α–His antibody GE Healthcare Life Sciences 27-4710-01 
NheI Fermentas ER0975 
Nitrocellulose membranes GE Healthcare Life Sciences RPN203D 
NP-40 Sigma NP40S 
NuPAGE LDS sample buffer Invitrogen NP0007 
NuPAGE Transfer Buffer  Life Technologies NP0006-1 
NZYColour Protein Marker II Nzytech MB090 
Optical quality sealing tape Bio-Rad MSB-1001 
PBS 
Sigma D5773 
Gibco 14190 
Lonza BE17-516F 
PD-10 columns GE Healthcare Life Sciences 17-0851-01 
PEI 
Sigma 40872-7 
PolySciences 23966 
Peristaltic pump P-1 GE Healthcare Life Sciences 18-1110-91 
pET47b(+) (kan
R
) Novagen 71461-3 
Pfu DNA polymerase Fermentas EP0501 
pGro7 (Cm
R
) TaKaRa 3340 
Pluronic F-68 Gibco 24040 
Potassium phosphate dibasic Prolabo 26931.263 
Potassium phosphate monobasic Prolabo 26936.293 
Power Broth (PB) AthenaES MD12-106-1 
Protease inhibitor cocktail Roche 11873580001 
SHuffle
®
 T7 express competent cells NEB C3029 
SimplyBlue SafeStain  Life Technologies LC6060 
Sodium chloride Carl Roth GmbH 9265.1 
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Reagent / Equipment Supplier Catalogue number 
Sodium phosphate dibasic Merck 1.06586 
Sodium phosphate monobasic Merck 1.06346 
SteriTop-GP Filter Unit Millipore SCGPT10RE 
Superose 6 PC 3.2/30 column  GE Healthcare Life Sciences 17-0673-01 
SYPRO Orange  Molecular Probes S6650 
T4 DNA ligase Fermentas EL0011 
TALON metal Affinity resin Clontech 635504 
Taq DNA polymerase  Fermentas EP0402 
Terrific Broth (TB) MoBio 12105-1 
TMAO Sigma 92277 
Tris Merck 108387 
Trypan blue 0.4% solution Gibco 15250-061 
Trypsin-EDTA Gibco 25300 
TunAir full baffle flasks Sigma Z710822 
Tween-20 Sigma P7949 
VacuCap Filter Unit 0.22µm filter  PALL Life Sciences 4628 
Western Lightning Plus-ECL Enhanced 
Chemiluminescence Substrate 
Perkin-Elmer NEL104001EA 
 
VI.2. Buffers  
1X SDS-PAGE Loading Buffer: 50mM Tris-Cl pH 6.8, 2% SDS, 0.1% Bromophenol Blue, 10% 
Glycerol, 100mM BME  
KPi: Potassium Phosphate buffer 
Na/KPi: Sodium / Potassium Phosphate buffer 
Home-made Lysis Buffer: 50mM KPi, 150mM NaCl, 1% NP-40, 1mM PMSF, 5% glycerol, pH 7.5 
VI.2.i  His6-hJAG2 DSL-EGF3 purification from soluble faction 
HisTrap Buffer A: 50mM Potassium Phosphate buffer, 500mM NaCl, 0.5% NP-40, 5mMmgCl2, 
20mM Imidazole, 5% Glycerol, 5mM BME, pH 7.5. 
Lysis Buffer: HisTrap Buffer A freshly supplemented with Protease inhibitor cocktail and 250 units 
of Benzonase. 
HisTrap Buffer B: 50mM Potassium Phosphate buffer, 150mM NaCl, 0.5% NP-40, 5mMmgCl2, 
1M Imidazole, 5% Glycerol, 5mM BME, pH 7.5. 
HRV-3C protease buffer: 20mM Tris, 150mM NaCl, 0.5mM EDTA, 10% Glycerol, 5mM BME, pH 8.0. 
SEC Buffer: 20mM Tris, 150mM NaCl, 10% Glycerol, 5mM BME, pH 8.0. 
VI.2.ii His6-hJAG2 DSL-EGF9 purification from soluble fration 
HisTrap Buffer A: 50mM Potassium Phosphate buffer, 500mM NaCl, 0.5% NP-40, 5mMmgCl2, 
50mM Imidazole, 5% Glycerol, 5mM BME, pH 7.5. 
Lysis Buffer: HisTrap Buffer A freshly supplemented with Protease inhibitor cocktail and 250 units 
of Benzonase. 
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HisTrap Buffer B: 50mM Potassium Phosphate buffer, 150mM NaCl, 5mMmgCl2, 1M Imidazole, 
5% Glycerol, 5mM BME, pH 7.5. 
VI.2.iii hJagged2 DSL-EGF3 inclusion bodies refolding tests 
Ressuspension / wash buffer: 50mM Tris, 100mM NaCl, 0.5% Triton X-100, pH 8.0. 
 
Solubilization buffer (I): 6M GuHCl, 50mM Tris, 100mM NaCl, 10mM DTT, pH 8.0 
Solubilization buffer (II): 8M Urea, 50mM Tris, 100mM NaCl, 10mM DTT, pH 8.0 
 
Refolding buffer A: 200mM Tris, 3.7mM Cystamine, 6.5mM Cysteamine, 1M L-Arginine, pH 8.0, 
Refolding buffer B: 20mM Tris, 1mM EDTA, 1mM GSH, 0.1mM GSSG, pH 8.0, 
Refolding buffer C:   200mM Tris, 3.7mM Cystamine, 6.5mM Cysteamine, 1M L-Arginine, 1M TMAO, 
pH 8.0; 
Refolding buffer D:   20mM Tris, 1mM EDTA, 1mM GSH, 0.1mM GSSG, 1M L-Arginine and 1M 
TMAO, pH 8.0. 
VI.2.iv hJagged2 DSL-EGF3 purification from inclusion bodies 
Solubilisation Buffer: 6M GuHCl, 50mM Na/K Pi, 150mM KCl, 10mM DTT, pH 7.0 
Refolding Buffer:         50mM Na/K Pi, 150mM KCl, 1mM EDTA, 1mM GSH, 0.1mM GSSG, 1M 
L-Arginine, pH 7.0 
Desalting buffer:        50mM Tris, 300mM NaCl, pH 7.5 
SEC Buffer:         50mM Na/KPi, 300mM NaCl, pH 7.0 
VI.2.v  hDelta-Like Ligand1 DSL-EGF6 purification at Oxford 
Cobalt beads wash buffer 1: PBS, 5mM Imidazole 
Cobalt beads wash buffer 2: PBS, 10mM Imidazole 
Cobalt beads elution buffer1: PBS, 350mM Imidazole 
SEC Buffer:   10mM Hepes, 150mM NaCl, pH 7.5 
VI.2.vi hDelta-Like Ligand1 DSL-EGF6 purification at iBET 
HisTrap Buffer A:  50mM Tris, 5mM CaCl2, pH 7.5 
HisTrap Buffer B:  50mM Tris, 5mM CaCl2, 300mM NaCl, 10mM Imidazole, pH 7.5 
HisTrap Buffer C:  50mM Tris, 5mM CaCl2, 1M Imidazole, pH 7.5 
SEC Buffer:  50mM Tris, 5mM CaCl2, 150mM NaCl 
VI.3. DSF Buffer screen plate layout 
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Table VI.2 - DSF Buffer and salt screen in a 96-well plate layout.  
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 
Glycine 
pH 3.0 
Citric Acid 
pH 3.2 
PIPPS 
pH 3.7 
Citric Acid 
pH 4.0 
Sodium 
Acetate 
pH 4.5 
Na / K Pi 
pH 5.0 
Sodium 
Citrate 
pH 5.5 
Na / K Pi 
pH 6.0 
Bis-Tris 
pH 6.0 
MES 
pH 6.2 
ADA 
pH 6.5 
Bis-Tris 
Propane 
pH 6.5 
B 
Ammonium 
Acetate 
pH 7.0 
MOPS 
pH 7.0 
Na / K Pi 
pH 7.0 
HEPES 
pH 7.5 
Tris 
pH 7.5 
EPPS 
pH 8.0 
Imidazole 
pH 8.0 
Bicine 
pH 8.5 
Tris 
pH 8.5 
CHES 
pH 9.0 
CHES 
pH 9.5 
CAPS 
pH 10.0 
C 
Glycine 
pH 3.0, 
150mM NaCl 
Citric Acid 
pH 3.2, 
150mM 
NaCl 
PIPPS 
pH 3.7, 
150mM 
NaCl 
Citric Acid 
pH 4.0, 
150mM 
NaCl 
Sodium 
Acetate 
pH 4.5, 
150mM 
NaCl 
Na / K Pi 
pH 5.0, 
150mM 
NaCl 
Sodium 
Citrate 
pH 5.5, 
150mM NaCl 
Na / K Pi 
pH 6.0, 
150mM 
NaCl 
Bis-Tris 
pH 6.0, 
150mM 
NaCl 
MES 
pH 6.2, 
150mM 
NaCl 
ADA 
pH 6.5, 
150mM 
NaCl 
Bis-Tris 
Propane 
pH 6.5, 
150mM NaCl 
D 
Ammonium 
Acetate 
pH 7.0, 
150mM NaCl 
MOPS 
pH 7.0, 
150mM 
NaCl 
Na / K Pi 
pH 7.0, 
150mM 
NaCl 
HEPES 
pH 7.5, 
150mM 
NaCl 
Tris 
pH 7.5, 
150mM 
NaCl 
EPPS 
pH 8.0, 
150mM 
NaCl 
Imidazole 
pH 8.0, 
150mM NaCl 
Bicine 
pH 8.5, 
150mM 
NaCl 
Tris 
pH 8.5, 
150mM 
NaCl 
CHES 
pH 9.0, 
150mM 
NaCl 
CHES 
pH 9.5, 
150mM 
NaCl 
CAPS 
pH 10.0, 
150mM NaCl 
E 
Glycine 
pH 3.0, 
500mM NaCl 
Citric Acid 
pH 3.2, 
500mM 
NaCl 
PIPPS 
pH 3.7, 
500mM 
NaCl 
Citric Acid 
pH 4.0, 
500mM 
NaCl 
Sodium 
Acetate 
pH 4.5, 
500mM 
NaCl 
Na / K Pi 
pH 5.0, 
500mM 
NaCl 
Sodium 
Citrate 
pH 5.5, 
500mM NaCl 
Na / K Pi 
pH 6.0, 
500mM 
NaCl 
Bis-Tris 
pH 6.0, 
500mM 
NaCl 
MES 
pH 6.2, 
500mM 
NaCl 
ADA 
pH 6.5, 
500mM 
NaCl 
Bis-Tris 
Propane 
pH 6.5, 
500mM NaCl 
F 
Ammonium 
Acetate 
pH 7.0, 
500mM NaCl 
MOPS 
pH 7.0, 
500mM 
NaCl 
Na / K Pi 
pH 7.0, 
500mM 
NaCl 
Hepes 
pH 7.5, 
500mM 
NaCl 
Tris 
pH 7.5, 
500mM 
NaCl 
EPPS 
pH 8.0, 
500mM 
NaCl 
Imidazole 
pH 8.0, 
500mM NaCl 
Bicine 
pH 8.5, 
500mM 
NaCl 
Tris 
pH 8.5, 
500mM 
NaCl 
CHES 
pH 9.0, 
500mM 
NaCl 
CHES 
pH 9.5, 
500mM 
NaCl 
CAPS 
pH 10.0, 
500mM NaCl 
G 
Glycine 
pH 3.0, 
150mM KCl 
Citric Acid 
pH 3.2, 
150mM KCl 
PIPPS 
pH 3.7, 
150mM KCl 
Citric Acid 
pH 4.0, 
150mM KCl 
Sodium 
Acetate 
pH 4.5, 
150mM KCl 
Na / K Pi 
pH 5.0, 
150mM KCl 
Sodium 
Citrate 
pH 5.5, 
150mM KCl 
Na / K Pi 
pH 6.0, 
150mM KCl 
Bis-Tris 
pH 6.0, 
150mM KCl 
MES 
pH 6.2, 
150mM KCl 
ADA 
pH 6.5, 
150mM KCl 
Bis-Tris 
Propane 
pH 6.5, 
150mM KCl 
H 
Ammonium 
Acetate 
pH 7.0, 
150mM KCl 
MOPS 
pH 7.0, 
150mM KCl 
Na / K Pi 
pH 7.0, 
150mM KCl 
HEPES 
pH 7.5, 
150mM KCl 
Tris 
pH 7.5, 
150mM KCl 
EPPS 
pH 8.0, 
150mM KCl 
Imidazole 
pH 8.0, 
150mM KCl 
Bicine 
pH 8.5, 
150mM KCl 
Tris 
pH 8.5, 
150mM KCl 
CHES 
pH 9.0, 
150mM KCl 
CHES 
pH 9.5, 
150mM KCl 
CAPS 
pH 10.0, 
150mM KCl 
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VI.4. MS/peptide fingerprinting report2 
 
Methodology: 
 
The protein band was destained, reduced, alkylated and digested with trypsin (Promega, 6.7ng/µl) 
overnight at 37°C. The tryptic peptides were desalted and concentrated using POROS R2 (Applied 
Biosystems) and eluted directly onto the MALDI plate using 0.6µl of 5mg/ml CHCA (alpha-cyano-4-
hydroxycinnamic acid, Sigma) in 50% (v/v) acetonitrile and 5% (v/v) formic acid. 
The data was acquired in positive reflector MS and MS/MS modes using a 4800plus MALDI-
TOF/TOF (AB Sciex) mass spectrometer and using 4000 Series Explorer Software v.3.5.3 (Applied 
Biosystems). External calibration was performed using Pepmix1 (Laser BioLabs). 
The fifteen most intense precursor ions from the MS spectra were selected for MS/MS analysis. 
The MS and MS/MS data were analyzed in combined search mode (MS+MS/MS) using GPS 
Explorer Software v.3.6 (Applied Biosystems) and MASCOT search engine. The search parameters 
were as follows: monoisotopic peptide mass values were considered, maximum precursor mass 
tolerance (MS) of 50ppm and a maximum fragment mass tolerance (MS/MS) of 0.3Da. The searches 
were performed against a custom protein database (containing the Sponsor’s protein sequences and 
the SwissProt protein database). A maximum of one missed cleavage was allowed. 
Carboxyamidomethylation of cysteines, oxidation of methionines, and deamidation of asparagines 
and glutamine were set as variable modifications. 
Protein identification was only accepted when significant protein homology scores were 
obtained (p<0.05) and at least one peptide was fragmented with a significant individual ion score 
(p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                     
2 Data provided/obtained by the Mass Spectrometry Unit (UniMS), ITQB/iBET, Oeiras, Portugal” 
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Results: 
 
Protein sequence coverage: 
 
 
   MASCOT SEARCH RESULTS 
PROTEIN VIEW 
Match to: sp|Dll1| Score: 499 Expect: 6.5e-045 
Dll1 DSL-EGF6 WITH SIGNAL PEPTIDE FROM VECTOR 
 
Nominal mass (Mr): 36229; Calculated pI value: 5.85 
NCBI BLAST search of sp|Dll1| against nr 
Unformatted sequence string for pasting into other applications 
 
Variable modifications: Carbamidomethyl (C),Deamidated (NQ),Gln->pyro- Glu (N-term 
Q),Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P Sequence Coverage: 34% 
 
Matched peptides shown in Red 
 
  1 MGELLLLLLL GLRLQLSLGA GAPGSSTGHH HHHHHHGSTG ENLYFQGASW 
 51 SQDLHSSGRT DLKYSYRFVC DEHYYGEGCS VFCRPRDDAF GHFTCGERGE 
101 KVCNPGWKGP YCTEPICLPG CDEQHGFCDK PGECKCRVGW QGRYCDECIR 
151 YPGCLHGTCQ QPWQCNCQEG WGGLFCNQDL NYCTHHKPCK NGATCTNTGQ 
201 GSYTCSCRPG YTGATCELGI DECDPSPCKN GGSCTDLENS YSCTCPPGFY 
251 GKICELSAMT CADGPCFNGG RCSDSPDGGY SCRCPVGYSG FNCEKKIDYC 
301 SSSPCSNGAK CVDLGDAYLC RCQAGFSGRH CDDN 
 
viii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Delta-like protein 1 OS=Homo sapiens GN=DLL1 PE=2 sp|O00548|DLL1_ 486 100 478 100 78003.6 0 8 52.311 
SV=2 HUMAN         
 
Peptide Information 
Calc. Mass  Obsrv.  Mass  ± da   ± ppm 
 
Start 
 
End Sequence  Ion 
 
C. I. % Modification 
 
Rank Result Type 
Seq. Seq. Score 
 
 
882.3887 882.3589 -0.0298 -34 431 438 CQAGFSGR  Carbamidomethyl (C)[1] Mascot 
1015.3972 1015.3843 -0.0129 -13 253 259 YCDECIR 30 0  Carbamidomethyl (C)[2,5] Mascot 
1015.3972 1015.3843 -0.0129 -13 253 259 YCDECIR  Carbamidomethyl (C)[2,5] Mascot 
1341.5927 1341.5757 -0.017 -13 420 430 CVDLGDAYLCR 83 100  Carbamidomethyl (C)[1,10] Mascot 
1341.5927 1341.5757 -0.017  -13 420 430   CVDLGDAYLCR Carbamidomethyl (C)[1,10] Mascot 
 
1411.5696 
 
1411.55 -0.0196  -14 
 
196 
 
207   DDAFGHFTCGER 101 
 
100  Carbamidomethyl (C)[9] 
 
Mascot 
 
1411.5696 
 
1411.55 -0.0196  -14 
 
196 
 
207   DDAFGHFTCGER Carbamidomethyl (C)[9] 
 
Mascot 
 
1417.5875 
 
1417.569 -0.0185  -13 
 
393 
 
404   CPVGYSGFNCEK Carbamidomethyl (C)[1,10] 
 
Mascot 
 
2115.8716 
 
2116.8555 
 
2116.8555 
 
2132.8506 
 
2438.0112 
 
2438.0112 
 
3211.3047 
 
3211.3047 
 
2115.8408 -0.0308  -15 
 
2116.8225 -0.033  -16 
 
2116.8225 -0.033  -16 
 
2132.8396 -0.011  -5 
 
2437.9646 -0.0466  -19 
 
2437.9646 -0.0466  -19 
 
3211.2551 -0.0496  -15 
 
3211.2551 -0.0496  -15 
 
362 
 
362 
 
362 
 
362 
 
177 
 
177 
 
218 
 
218 
 
380   ICELSAMTCADGPCFNG 
GR 
380   ICELSAMTCADGPCFNG 
GR 
380   ICELSAMTCADGPCFNG 
GR 
380   ICELSAMTCADGPCFNG 
GR 
195   FVCDEHYYGEGCSVFCR 
PR 
195   FVCDEHYYGEGCSVFCR 
PR 
244   GPYCTEPICLPGCDEQH 
GFCDKPGECK 
244   GPYCTEPICLPGCDEQH 
GFCDKPGECK 
 
Carbamidomethyl (C)[2,9,14] 
 
78  99.998  Carbamidomethyl (C)[2,9,14],  Deamidated 
(NQ)[16] 
Carbamidomethyl (C)[2,9,14],  Deamidated 
(NQ)[16] 
Carbamidomethyl (C)[2,9,14],  Deamidated 
(NQ)[16], Oxidation (M)[7] 
92  100  Carbamidomethyl (C)[3,12,16] 
Carbamidomethyl (C)[3,12,16] 
93  100  Carbamidomethyl (C)[4,9,13,20,26] 
Carbamidomethyl (C)[4,9,13,20,26] 
 
Mascot 
Mascot 
Mascot 
Mascot 
Mascot 
Mascot 
Mascot 
Mascot 
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VI.5. Cloning vector maps 
VI.5.1 pET-47b 
 
 
 
 
 
 
 
 
 
 
x 
 
VI.5.2 pHL-sec 
 
 
 
 
 
NOTE: The vector was supplied containing the 428bp efB2 insert to facilitate cloning. Adapted 
from Aricescu, Lu et al. (2006). 
 
 
 
 
 
 
 
 
 
xi 
 
 
VI.5.3 pTT22SSP4 
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